Topical and Peripherally Acting Analgesics

JANA SAWYNOK

Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada

Abstract——Acute nociceptive, inflammatory, and neuropathic pain all depend to some degree on the peripheral activation of primary sensory afferent neurons. The localized peripheral administration of drugs, such as by topical application, can potentially optimize drug concentrations at the site of origin of the pain, while leading to lower systemic levels and fewer adverse systemic effects, fewer drug interactions, and no need to titrate doses into a therapeutic range compared with systemic administration. Primary sensory afferent neurons can be activated by a range of inflammatory mediators such as prostanoids, bradykinin, ATP, histamine, and serotonin, and inhibiting their actions represents a strategy for the development of analgesics. Peripheral nerve endings also express a variety of inhibitory neuroreceptors such as opioid, α-adrenergic, cholinergic, adenosine and cannabinoid receptors, and agonists for these receptors also represent viable targets for drug development. At present, topical and other forms of peripheral administration of nonsteroidal anti-inflammatory drugs, opioids, capsaicin, local anesthetics, and α-adrenoceptor agonists are being used in a variety of clinical states. There also are some clinical data on the use of topical antidepressants and glutamate receptor antagonists. There are preclinical data supporting the potential for development of local formulations of adenosine agonists, cannabinoid agonists, cholinergic ligands, cytokine antagonists, bradykinin antagonists, ATP antagonists, biogenic amine antagonists, neuropeptide antagonists, and agents that alter the availability of nerve growth factor. Given that activation of sensory neurons involves multiple mediators, combinations of agents targeting different mechanisms may be particularly useful. Topical analgesics represent a promising area for future drug development.

Address correspondence to: Dr. Jana Sawynok, Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada B3H 4H7. E-mail: jana.sawynok@dal.ca

I. Introduction

Analgesic therapies for acute and chronic pain conditions currently rely on three major classes of drugs: nonsteroidal anti-inflammatory drugs (NSAIDs[1]), opioids, and a group of drugs with diverse pharmacological actions collectively known as adjuvants (e.g., antidepressants, anticonvulsants, local anesthetics, α_2-adrenoceptor agonists). Both NSAIDs and opioids exhibit a variety of adverse actions, and many chronic pain states, particularly those involving nerve injury, are not adequately controlled by these agents. With adjuvants, it is often necessary to titrate the dosage until adequate pain relief or intolerable side effects develop. Unfortunately, the latter outcome often occurs, and the degree of pain relief that results is only partial. The pharmacotherapy of chronic and neuropathic pain states has been described extensively in several recent reviews (Kingery, 1997; MacFarlane et al., 1997; Sindrup and Jensen, 1999; Watson and Watt-Watson, 1999; MacPherson, 2000).

An alternative approach to pain control is to apply drugs locally to the peripheral site of origin of the pain. This can be attained by the topical application of a cream, lotion, gel, aerosol, or patch to somatic sites or by injections directly into joints. With orofacial pain conditions, lozenges and mouthwashes also may be of use. These application methods allow for a higher local concentration of the drug at the site of initiation of the pain and lower or negligible systemic drug levels producing fewer or no adverse drug effects. Other potential advantages of localized applications are the lack of drug interactions, the lack of need to titrate doses to tolerability, and importantly, the ease of use. However, some degree of systemic absorption will occur following localized delivery methods, expecially with lipid soluble drugs, and the degree of systemic absorption needs to be assessed during the development of formulations. It is also important that potential local adverse effects be monitored carefully, both after topical delivery methods (e.g., cutaneous reactions), and following direct injections into joints (cf. Buerkle, 1999).

By definition, topical drugs used to control pain will act locally on damaged or dysfunctional soft tissues or peripheral nerves. Topical delivery systems differ from transdermal delivery systems in that they target a site immediately adjacent to the site of delivery rather than using the skin as an alternate systemic delivery system. Their actions may be on the inflammatory response itself (e.g., decreased production of inflammatory media-

tors, block of action of inflammatory mediators) or on sensory neurons (e.g., altered impulse generation through actions on up-regulated sodium channels, actions at specific receptors on the sensory neuron to attenuate activation of that neuron). Both acute and chronic pain conditions are likely to be amenable to this approach. In chronic pain states, the effectiveness of the approach may depend on the degree of inflammation, the degree of alteration in peripheral sensory processing, and the degree of central sensitization involved. Thus, chronic pain involves changes in both peripheral and central elements (Attal and Bouhassira, 1999; Raja et al., 1999; Baron, 2000; Bridges et al., 2001), and this approach is more likely to be effective where there is a prominent peripheral component. Recently, a mechanism-based classification of pain has been proposed as an alternative approach to prior taxonomies (Woolf et al., 1998; Woolf and Decosterd, 1999; Woolf and Mannion, 1999). Within this scheme, there is a prominent group of conditions in which primary afferents are involved, and these are the conditions that could exhibit the most benefit with this approach.

To date, there are only a limited number of topical therapies available for the relief of somatic pain (NSAIDs, capsaicin, lidocaine). With certain other local delivery methods (intra-articular injections), there is promising clinical data (morphine, clonidine). There is, however, considerable interest in the preclinical literature in identifying novel peripheral targets, and the development and formulation of this approach as a viable alternative to systemic therapies (e.g., Jones, 2000; Padilla et al., 2000). It is likely that in the next few years, several alternative modalities will become available for clinical use. The present review will consider both currently used topical analgesic therapies as well as emerging classes of agents. This is not an exhaustive review of the literature available on each of these modalities but rather a highlighting of the approach and a consideration of the potential for development.

II. Peripheral Pain Signaling

Significant advances in understanding pain signaling mechanisms and the pathophysiology of pain have occurred in the past decades. This has involved an appreciation of the diversity of the agents and the mechanisms that can modulate the pain signal in peripheral and central compartments, as well as an appreciation of the neurobiological changes that can occur in chronic pain states involving inflammation and nerve injury. Under normal physiological conditions, nociceptive signals are produced by intense stimulation of primary afferent sensory Aδ and C nerve fiber terminals by chemicals, heat, and pressure (Besson and Chaouch, 1987; Treede et al., 1992; Bevan, 1999; Millan, 1999; Raja et al., 1999). Sensory neurons can be divided into subgroups based on anatomical (fiber size, degree of

myelination, postsynaptic connections in the spinal cord), histochemical (presence of peptides and other neurotransmitters, presence of ion channels and receptors, regulation by growth factors), and physiological (responsiveness to sensory modalities, conduction velocity) properties (Lawson, 1996; Snider and McMahon, 1998; Caterina and Julius, 1999). Nociceptive signals are transmitted to the superficial layers of the dorsal spinal cord where they undergo substantial modulation by local mechanisms, as well as by projections from supraspinal structures, which can provide both inhibitory and facilitatory influences; further transmission to brainstem and thalamic sites, and subsequently to the cerebral cortex, then occurs (Basbaum and Fields, 1984; Besson and Chaouch, 1987; Fields and Basbaum, 1994; Millan, 1999). Chronic inflammation or nerve injury produce 1) alterations in the excitability of peripheral nerves and in the expression of neurotransmitters, enzymes, receptors, and ion channels in these nerves; 2) changes in blood flow and vascular permeability, in the activation and migration of immune cells, and in the release of growth and trophic factors from tissues surrounding the nerve; and 3) alterations in the spinal processing of pain (Woolf and Doubell, 1994; Doubell et al., 1999; Levine and Reichling, 1999; McMahon and Bennett, 1999; Raja et al., 1999; Woolf and Salter, 2000).

A diversity of chemical mediators that are produced or released locally following tissue injury or inflammation can activate peripheral sensory nerve endings (Fig. 1). These can directly activate the sensory nerve [e.g., H^+,

ATP, glutamate, 5-hydroxytryptamine (5-HT), histamine, bradykinin], sensitize the nerve ending to the action of other stimuli [e.g., prostaglandins and prostacyclin, cytokines such as interleukin-1β (IL-1β), IL-2, IL-6, IL-8, tumor necrosis factor-α], or exert regulatory effects on the sensory neuron, adjacent inflammatory cells, and sympathetic nerves [e.g., bradykinin, tachykinins, nerve growth factor (NGF)]. Some agents that activate sensory neurons do so by acting directly on ion channels (e.g., H^+ via acid-sensitive ion channels, ATP via P2X receptors, glutamate via ionotropic glutamate receptors), whereas other agents sensitize sensory neurons by acting on G-protein-coupled metabotropic receptors to alter intracellular messengers (e.g., cyclic AMP, Ca^{2+}, inositol trisphosphate), and some of these activate protein kinases (e.g., protein kinase A, protein kinase C) that then phosphorylate ion channels and modulate their function. The diversity of chemical mediators and the mechanisms involved in peripheral pain signaling have been described in detail in recent reviews (Bevan, 1999; Levine and Reichling, 1999; Millan, 1999).

Sensory nerve endings also express a number of receptors for neurotransmitters that can inhibit pain transmission (Fig. 1). Many of these receptors were characterized initially in the dorsal spinal cord (Yaksh, 1999), but some receptors that are synthesized in the cell body of dorsal root ganglia cells and transported centrally to reside presynaptically on primary afferent neurons also are transported peripherally (Coggeshall and Carlton, 1997). Axonal transport of neuroreceptors

INHIBITORY INFLUENCES:

opioids (μ, δ, κ)   GABA ($GABA_B$)
α_2-adrenoceptor (α_{2C})   orphanin (ORL_1)
adenosine (A_1)   somatostatin
cannabinoids (CB_1, CB_2)

immune cells

mast cell

platelets

TISSUE INJURY INFLAMMATION

sensory neuron

dorsal root ganglion

blood vessel

sympathetic nerves

spinal cord

EXCITATORY INFLUENCES:

prostanoids (EP, IP) α_2-adrenoceptor (α_{2A})
bradykinin (B_1, B_2)   glutamate (NMDA, AMPA, KA)
histamine (H_1)   acetylcholine (N)
serotonin ($5-HT_1, 5-HT_2, 5-HT_3, 5-HT_4$)   adenosine (A_{2A}, A_3)
ATP ($P2X_3$)   tachykinins (NK_1, NK_2)
   nerve growth factor (TrkA)

FIG. 1. Excitatory and inhibitory influences on peripheral nerve activity by mediators released by tissue injury and inflammation and by a variety of agents acting on neuroreceptors.

can be demonstrated following ligation of the nerve and detection of an accumulation of receptors proximal and distal to the ligature. For example, μ-, δ-, κ-opioid (Young et al., 1980; Laudron, 1984; Stein et al., 1990; Hassan et al., 1993), and cannabinoid receptors (Hohmann and Herkenham, 1999b) have been detected in this manner. Other inhibitory receptors, such as γ-aminobutyric acid$_A$ (GABA$_A$) receptors (Carlton et al., 1999), have been visualized directly on peripheral nerve profiles. Although not all receptors that are transported centrally are necessarily also transported peripherally (Coggeshall and Carlton, 1997), it is likely that the peripheral receptor profile of sensory nerve terminals, as well as the alterations in these induced by inflammation and nerve injury, remains incompletely characterized. Regardless of whether there is direct evidence for a particular receptor to be localized on sensory afferents, there is a mounting body of evidence that many of these neurotransmitters have been well characterized in the spinal cord and exert significant peripheral effects on pain transmission by acting directly on sensory nerves. Such evidence will be considered in subsequent sections.

III. Topical and Peripherally Acting Analgesics

A. Nonsteroidal Anti-Inflammatory Drugs

The NSAIDs are among the most widely used of all therapeutic classes of drugs. These agents have been understood for many years to act peripherally to reduce the production of prostaglandins that sensitize nerve endings at the site of injury (Vane, 1971). This effect occurs due to inhibition of the cyclooxygenase (COX) enzyme that converts arachidonic acid liberated from the phospholipid membrane by phospholipases to prostanoids such as prostaglandins. Two forms of COX are well characterized, a constitutive form (COX1) that is normally expressed in tissues such as stomach and kidney and plays a physiological role in maintaining tissue integrity, and a form that is induced by inflammatory mediators (COX2) and plays a significant role in pain and inflammation (Vane et al., 1998). The analgesic actions of NSAIDs can be dissociated from anti-inflammatory effects, and this may reflect additional spinal and supraspinal actions of NSAIDs to inhibit various aspects of central pain processing (Yaksh et al., 1998). Both COX isoforms contribute to spinal and supraspinal prostanoid production following tissue injury or inflammation (Yaksh et al., 1998). A major recent drug development that has occurred in an attempt to minimize certain adverse effects with NSAIDs has been the development of selective COX2 inhibitors (Vane and Botting, 1998). This strategy targets the production of prostaglandins specifically involved in pain and inflammation while sparing constitutive prostaglandins that exert important physiological roles such as maintaining the integrity of the gastric lining and normal renal function. A further enzyme, COX3, has recently been described; this

has a prominent central distribution, is selectively inhibited by acetaminophen, and is potently inhibited by NSAIDs (Chandrasekharan et al., 2002). Its identification has the potential to explain a number of unresolved issues regarding the pharmacology of NSAIDs as analgesics (Warner and Mitchell, 2002).

An additional strategy to try to minimize adverse effects has been the development of topical formulations of NSAIDs, as this can minimize plasma concentrations of drugs and lead to fewer adverse effects at sites remote from the area of application. Bioavailability and plasma concentrations following topical application are 5 to 15% of those achieved by systemic delivery (Heyneman et al., 2000). In human experimental pain paradigms, topical application of NSAIDs produces analgesia in models of cutaneous pain (Steen et al., 1995, 1996; Schmelz and Kress, 1996; McCormack et al., 2000) and muscle pain (Steen et al., 2001). In a clinical context, there have been three substantial reviews of the efficacy of topical NSAIDs (Moore et al., 1998; Vaile and Davis, 1998; Heyneman et al., 2000). One of these addressed applications in musculoskeletal and soft tissue injuries (e.g., sprains, strains, tendonitis) and rheumatic diseases (Vaile and Davis, 1998), another accessed a wider database including company trials (86 trials, >10,000 patients; Moore et al., 1998), and the third focused on efficacy and safety, primarily in chronic rheumatic diseases (Heyneman et al., 2000). Each overview concluded that there was clear evidence to support efficacy of topical NSAIDs given by gel, spray, or patch for such conditions. A multi-center trial of an NSAID patch for sports-related soft tissue injury found similar benefit (Galer et al., 2000).

When NSAIDs are administered topically, relatively high concentrations occur in the dermis, whereas levels in the muscle are at least equivalent to those following systemic administration (Heyneman et al., 2000). Topically applied NSAIDs do reach the synovial fluid, but it is not clear whether this reflects local penetration or results from systemic circulation (Vaile and Davis, 1998). In osteoarthritis and rheumatoid arthritis, the effects of topical NSAIDs may be modest, and efficacy can be quite variable ranging from 18 to 92% (Heyneman et al., 2000). This may be due to high placebo rates in rheumatic diseases, use of rescue medications, and significant variability in percutaneous absorption rates.

Adverse effects with topical NSAIDs can generally be divided into cutaneous and systemic reactions. Adverse drug reactions occur in up to 10 to 15% of patients, and cutaneous reactions (rash, pruritis at site of application) account for most of these (Moore et al., 1998; Heyneman et al., 2000). Adverse systemic effects, such as gastrointestinal effects, occur less frequently but are more likely in patients who have previously demonstrated such responses to oral preparations (Vaile and Davis, 1998).

B. Opioids

The central effects of opioids on pain transmission by actions within the dorsal horn of the spinal cord and at brainstem and other supraspinal sites have been recognized for some time. It is known now that opioid receptors also are present on the peripheral terminals of thinly myelinated and unmyelinated cutaneous sensory fibers (Coggeshall et al., 1997). Dorsal root ganglia contain mRNA for opioid receptors (Maekawa et al., 1994; Minami et al., 1995), and when synthesized, these receptors are transported both centrally (Coggeshall and Carlton, 1997) and peripherally (Stein et al., 1990; Hassan et al., 1993). Peripheral opioid actions are not prominent in normal tissue but appear early after the induction of inflammation (Stein, 1993; Schäfer et al., 1995; Zhou et al., 1998). Although inflammation enhances opioid receptor expression and transport to peripheral nerve terminals (Hassan et al., 1993), this process takes days and the initial expression of analgesia precedes these changes (minutes to hours). The early effect is due to inflammation disrupting the perineurial barrier that normally limits the access for drugs to the nerve (Antonijevic et al., 1995). Thus, following such disruption, opioids have access to the nerve terminal and the receptors that are normally present (Dado et al., 1993; Coggeshall et al., 1997). The lowered pH at inflammatory sites may also enhance opioid receptor coupling to G-proteins (Selley et al., 1993).

There are a large number of behavioral studies that have examined peripheral antinociceptive effects of exogenous opioids, and these effects have been demonstrated primarily using models of inflammation (Stein, 1993, 1995; Machelska et al., 1999). μ-Opioid receptor agonists are generally the most potent at producing peripheral analgesia, with δ- and κ-opioid receptor agonists being less active. However, effects can depend on the nature of the noxious stimulus and the type of inflammation (i.e., differences manifest depending on whether an acute model such as intraplantar prostaglandin E_2 is used or whether a more chronic model such as Freund's adjuvant is used).

Opioid receptors are present on several distinct peripheral targets including sensory nerves, sympathetic postganglionic neurons, and immune cells. Antinociception by μ-, δ-, and κ-opioid agonists in inflammation results from actions on sensory nerves rather than sympathetic neurons (Zhou et al., 1998). Although opioid receptors are present on a variety of immune cells and activation can modulate proliferation and several of their functions (e.g., chemotaxis, superoxide production, mast cell degranulation), these immunomodulatory actions can be stimulatory as well as inhibitory, and their significance in relation to antinociception has not been determined (Stein et al., 1997). Activation of peripheral opioid receptors on sensory nerve terminals results in interactions with G-proteins (G_i and/or G_o), a decrease in cyclic AMP in the sensory nerve terminal, an increased K^+ efflux, and a decreased Ca^{2+} entry, and these attenuate the excitability of the peripheral nerve terminal, the propagation of action potentials, and release of neuropeptides (Stein et al., 1997; Machelska et al., 1999). A recent study also reports analgesia following peripheral administration of morphine in a model of nerve injury where inflammation is not prominent (Pertovaara and Wei, 2001). This particular action may reflect an involvement of the sympathetic nervous system as chemical sympathectomy augments such analgesia.

A number of studies have addressed the issue of whether peripheral opioid mechanisms are of significance in a clinical setting. Some studies have examined experimental pain, but the largest number of studies have examined the intra-articular application of morphine (0.5–10 mg) during knee surgery (Stein and Schäfer, 1997; Stein et al., 1997; Kalso et al., 2002). The majority of studies report significant effects by at least one pain measure (visual analog scale, numerical scales, verbal scales, supplementary analgesia consumption, or time to first supplementary analgesic), provided adequate doses are used (3–5 mg). Effects are reversible by naloxone, similar in magnitude to conventional local anesthetics, and can last up to 48 h after injection. Peripheral analgesia with morphine also has been observed in dental surgery (Likar et al., 1998, 2001). Local analgesic actions of morphine also have been examined in arthritis, a condition involving more chronic inflammation. In such studies, the intra-articular injection of morphine (1–3 mg) produced a long-lasting analgesia (up to 6 days) (Likar et al., 1997; Stein et al., 1999). Morphine also reduced synovial leukocyte counts indicating that a possible anti-inflammatory effect also may have contributed to the pain relief (Martinez et al., 1996; Wilson et al., 1996, 1998). No adverse effects of morphine were noted, and it was concluded that opioids may be a promising novel class of intra-articular agents for chronic arthritis that is devoid of central side effects such as respiratory depression, sedation, dependence, or addiction when given by this method.

In addition to the peripheral delivery of opioids by localized injection, opioids may also produce benefits following topical application to somatic sites. In preclinical studies using a model of thermal injury-induced hyperalgesia, loperamide (an opioid not systemically absorbed following oral administration) was shown to produce an antihyperalgesic effect following topical application to the rat hindpaw (Nozaki-Taguchi and Yaksh, 1999). Another model, that of immersing the tail of a mouse into a solution containing dimethyl sulfoxide with morphine or DAMGO (another μ-opioid receptor agonist), also reveals a local peripheral action by μ-opioids (Kolesnikov and Pasternak, 1999a,b). Interestingly, repeated administration of the opioid produced tolerance to the peripheral analgesia, and this was both reversed and prevented by N-methyl-D-aspartate (NMDA) recep-

tor antagonists (Kolesnikov and Pasternak, 1999a,b). Earlier studies had demonstrated that repeated peripheral injection of morphine could produce a peripheral analgesia and tolerance (Aley et al., 1995; Aley and Levine, 1997a), and the latter involved nitric oxide (Aley and Levine, 1997b). Peripheral opioid analgesia thus exhibits tolerance just as when opioids are administered by other routes, such as via spinal routes, where the mechanism of tolerance also involves NMDA receptors and nitric oxide (Mao, 1999).

The topical route of opioid administration has recently been employed in clinical contexts as well, and there are several case reports attesting to its effectiveness. Thus, topical opioids produce analgesia when applied to painful ulcers and skin lesions (Back and Finlay, 1995; Twillman et al., 1999; Ballas, 2002), following burns (Long et al., 2001), and in cutaneous pain in a palliative care setting (Krajnik et al., 1999). Given that side effects resulting from these applications are minimal, this approach represents a mode of delivery of opioids that warrants further clinical attention. Factors determining bioavailability following such application (e.g., specific formulations, degree of absorption from healthy versus inflamed or lesioned skin), as well as the potential for cutaneous side effects (e.g., via histamine release) will need to be evaluated systematically.

C. Capsaicin

Capsaicin is a natural constituent in pungent red chili peppers. Depending on the concentration used and the mode of application, capsaicin can selectively activate, desensitize, or exert a neurotoxic effect on small diameter sensory afferent nerves while leaving larger diameter afferents unaffected (Holzer, 1991; Winter et al., 1995). Sensory neuron activation occurs due to interaction with a ligand-gated nonselective cation channel termed the vanilloid receptor (VR-1) (Caterina et al., 1997), and receptor occupancy triggers Na^+ and Ca^{2+} ion influx, action potential firing, and the consequent burning sensation associated with spicy food or capsaicin-induced pain. VR1 receptors are present on both C and Aδ fibers, and can be activated by capsaicin and its analogs, heat, acidification, and lipid metabolites (Tominaga et al., 1998; Caterina and Julius, 2001). Desensitization occurs with repeated administration of capsaicin, is a receptor-mediated process, and involves Ca^{2+}- and calmodulin-dependent processes and phosphorylation of the cation channel (Winter et al., 1995; Wood and Docherty, 1997). Capsaicin induces release of substance P and calcitonin gene-related peptide from both peripheral and central terminals of sensory neurons, and desensitization inhibits such release (Holzer, 1991); such inhibition may result from inhibition of voltage-gated Ca^{2+}-currents (Docherty et al., 1991; Winter et al., 1995). Neurotoxicity is partially osmotic and partially due to Ca^{2+} entry with activation of Ca^{2+}-sensitive proteases (Wood et al., 1989; Winter et al., 1995). In neo-

nates, neurotoxicity can be lifelong (Janscó et al., 1977), whereas in adult animals receiving a localized dose, a reversible injury may occur as cell bodies capable of regeneration are left intact (Holzer, 1991). Both desensitization and neurotoxicity lead to analgesia in rodent paradigms, with specific characteristics of analgesia depending on the dose of capsaicin, route of administration, treatment paradigm (i.e., acute or repeated administration), and age of the animal (Holzer, 1991; Winter et al., 1995). The topical skin application of capsaicin to rodents produces analgesia (Kenins, 1982; Lynn et al., 1992), but variability in outcome can occur due to the concentration, the number of applications, and the different vehicles used that can affect the rate and extent of skin penetration (Carter and Francis, 1991; McMahon et al., 1991).

Acute intradermal injection of capsaicin to the skin in humans produces a burning sensation and flare response; the area of application becomes insensitive to mechanical and thermal stimulation, the area of flare exhibits a primary hyperalgesia to mechanical and thermal stimuli, and an area beyond the flare exhibits secondary allodynia (Simone et al., 1989; LaMotte et al., 1991). Repeated application to normal skin produces desensitization to this response and thus forms the basis of the therapeutic use of topical capsaicin in humans. Desensitization involves both physiological changes in the terminals of the sensory neuron noted above, as well as a degree of loss of sensory fiber terminals within the epidermis (Simone et al., 1998; Nolano et al., 1999).

Topical capsaicin preparations of 0.025 and 0.075% are available for human use, and these produce analgesia in randomized double-blind placebo-controlled studies, open label trials, and clinical reports (Watson, 1994; Rains and Bryson, 1995). Topical capsaicin produces benefit in postherpetic neuralgia (Bernstein et al., 1989; Watson et al., 1993), diabetic neuropathy (Capsaicin Study Group, 1992), postmastectomy pain syndrome (Watson and Evans, 1992; Dini et al., 1993), oral neuropathic pain, trigeminal neuralgia, and temperomandibular joint disorders (Epstein and Marcoe, 1994; Hersh et al., 1994), cluster headache (following intranasal application) (Marks et al., 1993), osteoarthritis (McCarthy and McCarthy, 1992), and dermatological and cutaneous conditions (Hautkappe et al., 1998). Whereas pain relief is widely observed in these studies, the degree of relief is usually modest, although some patients have a very good result. Topical capsaicin is generally not considered a satisfactory sole therapy for chronic pain conditions and is often considered an adjuvant to other approaches (Watson, 1994). No significant benefit was reported in chronic distal painful neuropathy (Low et al., 1995) or with human immunodeficiency virus-neuropathy (Paice et al., 2000).

The most frequently encountered adverse effect with capsaicin is burning pain at the site of application, particularly in the first week of application. This can make

it impossible to blind trials and can lead to dropout rates ranging from 33 to 67% (Watson et al., 1993; Paice et al., 2000). Another factor in compliance is the time delay before therapeutic effect is observed (at least a week, but sometimes several weeks). One approach toward minimizing adverse effects and accelerating the rate of analgesia has been to deliver a higher capsaicin concentration (5–10%) under regional anesthesia, and this produced sustained analgesia lasting 1 to 8 weeks in cases of complex regional pain syndrome and neuropathic pain (Robbins et al., 1998). When topical local anesthetics were applied with 1% topical capsaicin, no alteration in pain produced by the capsaicin was observed in healthy subjects (Fuchs et al., 1999) indicating that this cotreatment was not sufficient to block the pain induced by capsaicin.

D. Local Anesthetics

Voltage-gated sodium channels (VGSCs) play a fundamental role in the control of neuronal excitability, and a family of genes encoding α-subunits of the channel have been identified (Catterall, 2000). Sensory neurons contain both classical VGSCs that are sensitive to inhibition by tetrodotoxin, as well as several atypical VGSCs that are relatively resistant to tetrodotoxin, and some tetrodotoxin-resistant subtypes are selectively expressed in sensory afferent neurons (McClesky and Gold, 1999; Waxman et al., 1999). Alterations in the expression, distribution, and function of VGSCs that occur following nerve injury or chronic inflammation have a profound effect on the firing of primary afferent neurons and contribute to the expression of pain behaviors (Devor and Seltzer, 1999; McCleskey and Gold, 1999; Raja et al., 1999).

In neuropathic pain, a major factor that contributes to the initiation and maintenance of ectopic repetitive firing of primary afferents following injury appears to be redistribution of VGSCs along injured axons, and this causes an abnormal accumulation and increased membrane density of sodium channels at focal sites of injury, which then contributes to a lower threshold for activation and ectopic impulse generation (Devor and Seltzer, 1999; Raja et al., 1999). Local anesthetics that block VGSCs have long been used to abolish pain temporarily by blocking nerve conduction, but local anesthetics are now used as an effective treatment for many chronic pain conditions. Thus, the increased sensitivity of ectopic activity to local anesthetics and the use-dependent nature of channel block allow for the block of spontaneous and evoked activity (impulse generation) without affecting nerve conduction (impulse propagation) (Fields et al., 1997; Hunter, 1999). Systemically administered local anesthetics such as i.v. lidocaine, oral mexilitine, and oral tocainamide are effective in a number of chronic pain conditions (Fields et al., 1997; Kingery, 1997; MacFarlane et al., 1997). Such regimens produce analgesia in diabetic neuropathy (Dejgard et al., 1988; Bach et al.,

1990), neuralgias (Rowbotham et al., 1991; Marchettini et al., 1992), peripheral nerve injury (Chabal et al., 1992; Galer et al., 1996), and reflex sympathetic dystrophy (Edwards et al., 1985; Galer et al., 1993). However, despite this efficacy in different clinical pain conditions, systemic local anesthetics are limited by their adverse central nervous system (dizziness, lightheadedness, somnolence) and cardiac effects.

Topical formulations of local anesthetics may be an effective alternative to systemic delivery systems for chronic pain. Such formulations are widely used as topical anesthetics for minor acute surgical procedures (Lener et al., 1997), and there are some reports of use in chronic pain conditions such as postherpetic neuralgia (Stow et al., 1989; Attal et al., 1999; but see Devers and Galer, 2000). Clinical attention has focused recently on topical formulations of lidocaine. Thus, topical lidocaine as a 5% gel (Rowbotham et al., 1995) or patch (Rowbotham et al., 1996) provides effective pain relief in postherpetic neuralgia with no systemic adverse effects. The patch itself provided some pain relief, likely due to the protection afforded to allodynic skin (Rowbotham et al., 1996). A subsequent study used a novel time-to-study-exit criterion and an enriched enrolment design, and the lidocaine patch produced a significantly prolonged time to exit without systemic side effects (Galer et al., 1999). An open label study noted clinically meaningful pain relief in a variety of neuropathic pain conditions (Devers and Galer, 2000). This delivery method was regarded as effective, safe, and convenient and was proposed as a first line therapy for postherpetic neuralgia, especially in the elderly who are more susceptible to systemic side effects.

In addition to VGSCs, voltage-gated Ca^{2+} channels play an important role in primary afferent function by regulating transmitter release, second messenger signal transduction pathways, and gene expression. Whereas multiple types of Ca^{2+} channels are localized on sensory neurons, N-type channels have a high density in laminae I and II of the dorsal spinal cord (Gohil et al., 1994), and the spinal application of blockers of these channels produces analgesia in several models of acute and chronic pain (Malmberg and Yaksh, 1994, 1995). In models of nerve injury pain, the local administration of N-type Ca^{2+} channel blockers to the spinal cord (Chaplan et al., 1994; Bowersox et al., 1996), the site of injury (Xiao and Bennett, 1995), and peripheral sites in the receptive field (White and Cousins, 1998) can alleviate manifestations of nerve injury pain. Interestingly, altered functioning of G-protein-coupled Ca^{2+} currents in sensory neurons is implicated in diabetic neuropathy (Hall et al., 2001), and Ca^{2+} channels may represent a further target in neuropathic pain states.

E. Antidepressants

Antidepressants given systemically have been used to treat chronic pain for 40 years (Sindrup, 1997). Initially,

efficacy in this condition was attributed to central actions within the spinal cord and at supraspinal sites (Sindrup, 1997; Eschalier et al., 1999). Recently, the local peripheral administration of antidepressants was demonstrated to produce analgesia in the formalin model of tonic pain (Sawynok et al., 1999a,b) and a model of neuropathic pain (Esser and Sawynok, 1999). Peripheral activity also was noted in a visceral pain model (Su and Gebhart, 1998). Several antidepressants are active in the formalin test including desipramine, imipramine, nortriptyline, doxepin, and fluoxetine (Sawynok et al., 2000a). Local release of adenosine and activation of adenosine A_1 receptors is involved in the action of amitriptyline, as analgesia is reduced by adenosine receptor antagonists (Sawynok et al., 1999a; Esser and Sawynok, 2000), and local administration of amitriptyline enhances the peripheral availability of adenosine (Liu et al., 2000b). However, antidepressants produce a range of acute pharmacological actions including inhibition of noradrenaline (NA) and 5-HT reuptake, inhibition of NMDA, nicotinic, histamine, and 5-HT receptors, and block of ion channels (Sindrup, 1997; Eschalier et al., 1999), and a number of these actions, and even combinations of these actions, may contribute to the local peripheral efficacy of antidepressants (Sawynok et al., 2000a). Additional actions of antidepressants are expressed following chronic administration (Leonard, 1996; Duman et al., 1997; Skolnick, 1999), but the contribution of these actions to analgesia by antidepressants, following either systemic or local administration, remains to be determined.

The antidepressant doxepin is available as a cream for the treatment of eczema (Drake et al., 1995; Smith and Corelli, 1997). Topical doxepin cream has been reported to produce analgesia in two randomized double-blind placebo-controlled studies with chronic neuropathic pain (McCleane, 2000a,b). In the first study, doxepin (5%) was applied for 4 weeks, and produced significant analgesia in the last 10 days of treatment, but not in the 1st week. In the larger study, topical doxepin (3.3%) was compared with topical capsaicin (0.025%) and a combination of doxepin with capsaicin. Significant reductions in overall pain scores were observed for all treatment groups from week 2 to 4, but the combination group had a faster onset of action with analgesia at 1 week. A burning discomfort after cream application was noted by 81% in the capsaicin group, 61% in the doxepin/capsaicin group, and 17% in the doxepin group. Interestingly, a recent study reported that doxepin, formulated as a mouthwash, produces analgesic actions in patients with oral mucosal pain due to cancer or cancer therapy (Epstein et al., 2001). Antidepressants exhibit promise as a useful class of agents to be used as analgesics following topical application and other methods of local delivery.

F. Glutamate Receptor Antagonists

Within the dorsal spinal cord, both ionotropic glutamate receptors [NMDA, α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA), kainic acid (KA)] and metabotropic glutamate receptors are involved in nociceptive signaling and central sensitization in conditions of chronic pain (Coderre et al., 1993; Dickenson, 1994; Price et al., 1994; Dickenson et al., 1997). Both the systemic and spinal administration of multiple classes of glutamate receptor antagonists have been observed to produce analgesia in a variety of persistent pain models, and although their potential for development as a novel class of analgesics has been considered, this may be hampered by the presence of adverse motor and other effects (Coderre, 1999; Fisher et al., 2000).

More recently, it has been appreciated that multiple glutamate receptors also are expressed on peripheral nerve terminals, and these may contribute to peripheral nociceptive signaling. Ionotropic and metabotropic glutamate receptors are present on membranes of unmyelinated peripheral axons and axon terminals in the skin (Carlton et al., 1995; Zhou et al., 2001b), and peripheral inflammation increases the proportions of both unmyelinated and myelinated nerves expressing ionotropic glutamate receptors (Carlton and Coggeshall, 1999). Local injections of NMDA and non-NMDA glutamate receptor agonists to the rat hindpaw (Jackson et al., 1995; Zhou et al., 1996) or knee joint cavity (Lawland et al., 1997) enhance pain behaviors generating hyperalgesia and allodynia. Intraplantar injection of metabotropic glutamate receptor agonists produces similar actions (Walker et al., 2001; Zhou et al., 2001b). On the other hand, local administration of antagonists for both ionotropic (Davidson et al., 1997; Davidson and Carlton, 1998) and metabotropic receptors (Bhave et al., 2001; Zhou et al., 2001b) inhibits pain behavior evoked by formalin, as well as hyperalgesia produced by kaolin and carrageenan injected into the knee joint (Lawland et al., 1997). Inflammation of the hindpaw (Omote et al., 1998) or the knee joint produces a local release of glutamate (Lawland et al., 2000) that appears to originate from A and C fibers (deGroot et al., 2000). An additional indirect mechanism, via activation of glutamate receptors on sympathetic afferents to release NA and other substances from postganglionic efferents (e.g., ATP, neuropeptide Y), could occur as NMDA, AMPA, and KA receptors also are present on postganglionic sympathetic efferents, and inflammation enhances the expression of such receptors (Coggeshall and Carlton, 1999). Collectively, these results suggest the involvement of local release of glutamate and activation of both ionotropic and metabotropic glutamate receptors in inflammatory pain in particular, and raises the possibility that topical formulations of such agents might be a useful strategy to develop for such conditions (Carlton, 2001). It is also possible that peripheral glutamate receptors play a significant role in peripheral pain signaling in neuropathic pain (as occurs at spinal sites), but direct data regarding this are not yet available.

There is some evidence in humans to support a peripheral site of action for ketamine, a noncompetitive NMDA receptor antagonist, in reducing pain responses. In a study of acute postoperative pain, ketamine enhanced local anesthetic and analgesic effects of bupivacaine by a peripheral mechanism (Tverskoy et al., 1996). In a thermal injury model in healthy volunteers, subcutaneous injection of ketamine produced a long-lasting reduction in hyperalgesia in one study (Warncke et al., 1997) but only produced a brief analgesia with no effect on hyperalgesia in another such study (Pedersen et al., 1998). Following intradermal injection of capsaicin to healthy volunteers, peripheral ketamine had no effect on any pain outcome measures whereas peripheral lidocaine reduced all such measures (Gottrup et al., 2000). It appears that analgesic effects following peripheral administration of ketamine are variable and may be condition-dependent. It should be noted that ketamine also produces local anesthetic actions, blocks voltage-sensitive Ca^{2+} channels, alters cholinergic and monoaminergic actions and interacts with opioid mechanisms, and these actions also may contribute to its analgesic profile (Hirota and Lambert, 1996; Meller, 1996; Sawynok and Reid, 2002). The peripheral contribution of glutamate receptors to pain may be more pronounced in conditions involving chronic inflammation where up-regulation of receptors occurs (see above), or in conditions of nerve injury. In humans, a recent report has demonstrated that in the synovial fluid of arthritis patients, concentrations of both glutamate and aspartate are elevated (McNearney et al., 2000). There are also some case reports regarding the efficacy of ketamine administered topically for sympathetically maintained pain (Crowley et al., 1998) and for pain in a palliative setting (Wood, 2000). These observations support the notion that targeting peripheral glutamate receptors in inflammatory and chronic pain states may represent a useful option to explore for pain treatment.

G. α-Adrenoceptor Agonists

There is evidence from both clinical and preclinical studies that the sympathetic nervous system contributes to pain following nerve injury (Jänig et al., 1996; Perl, 1999; Michaelis, 2000). Clinically, when hyperalgesia and allodynia resulting from nerve injury are relieved by sympathetic or adrenergic blockers, it is termed sympathetically maintained pain, and such disorders are now regarded as complex regional pain syndromes (Stanton-Hicks et al., 1995). Normally, sympathetic mechanisms do not cause excitation of primary afferent neurons. However, following experimentally induced nerve injury, the following may be observed: 1) coupling occurs between sympathetic fibers and afferent terminals in the neuroma following nerve cut or ligation, and sympathetic stimulation or NA can cause excitation of unmyelinated nerves; 2) coupling occurs between unlesioned postganglionic and afferent nerve terminals fol-

lowing partial nerve lesions; and 3) sympathetic nerve terminals enter the dorsal root ganglia and form basket-like structures around dorsal root ganglia cell bodies, particularly larger diameter cells, providing a collateral innervation from sympathetic terminals that normally supply blood vessels (Jänig et al., 1996; Perl, 1999; Michaelis, 2000). Thus, sympathetic-afferent coupling occurs at three distinct sites; at the site of injury, at the sensory terminal, and within dorsal root ganglia. The relative contributions of these mechanisms to sympathetic-afferent coupling in the different nerve injury conditions is highly dependent on the location and nature of the lesion, as well as on the time following the injury; as a consequence, sympathectomy can relieve the different manifestations of neuropathic pain (hyperalgesia and allodynia) in various nerve injury models to varying degrees (Kim et al., 1997; Lee et al., 1998; Ramer and Bisby, 1999).

Both behavioral and electrophysiological studies indicate that α_2-adrenoceptors are primarily mediators of sympathetic-afferent coupling following nerve injury (Sato and Perl, 1991, 1999; Tracey et al., 1995a; Chen et al., 1996; Moon et al., 1999). Multiple α_2-adrenoceptors have been detected in rat dorsal root ganglia, with α_{2C} on most, α_{2A} on some, and α_{2B} on few neurons (Cho et al., 1997; Shi et al., 2000). Nerve ligation or transection results in an up-regulation of α_{2A}-adrenoceptors, and a decrease or no change in α_{2C}-adrenoceptors in rat dorsal root ganglia (Cho et al., 1997; Birder and Perl, 1999; Shi et al., 2000). Afferent excitation following nerve injury is thought to result from α_{2A}-adrenoceptor activation (Perl, 1999; Kingery et al., 2000). α_1-Adrenoceptors also are involved in such activation in some conditions (Chen et al., 1996; Lee et al., 1999).

The sympathetic nervous system also contributes to hyperalgesia following tissue injury and inflammation, but the nature of the involvement in this case differs from that in nerve injury (Jänig et al., 1996). Inflammation does not lead to up-regulation of α_{2A}-adrenoceptors in dorsal root ganglia (Birder and Perl, 1999), and in this case, the enhancing effects of NA on the sensitivity of primary afferents may be mediated indirectly by actions on sympathetic postganglionic nerves (Levine et al., 1986; Jänig et al., 1996). α_2-Adrenoceptor activation also can produce analgesia following localized administration in an inflammation model (Khasar et al., 1995; Aley and Levine, 1997a). Hyperalgesia is proposed to be mediated by α_{2B}-adrenoceptors located on sympathetic postganglionic neurons, and analgesia by α_{2C}-adrenoceptors on primary afferent terminals (Khasar et al., 1995). The α_{2C}-receptor on primary afferents may exist as part of a trireceptor complex along with μ-opioid and adenosine A_1 receptors (Aley and Levine, 1997a).

Clonidine, an α_2-adrenoceptor agonist commonly used in the treatment of hypertension, is available as a patch for transdermal administration and has been used in chronic pain conditions. Transdermal clonidine relieved

symptoms of neuropathic pain in a subset of patients with diabetic neuropathy through a systemic action (Bayas-Smith et al., 1995). Clonidine patches also relieved hyperalgesia in some patients with sympathetically maintained pain due to a localized action, but had no effect on hyperalgesia in cases of sympathetically independent pain (Davis et al., 1991). Clonidine applied as a cream relieved orofacial neuralgia-like pain but was less effective against orofacial neuropathic pain (Epstein et al., 1997). Other studies reveal that local application of NA into symptomatic skin aggravates pain and mechanical or thermal hyperalgesia in some patients with sympathetically maintained pain (Torebjörk et al., 1995; Ali et al., 2000), peripheral nerve injury (Chabal et al., 1992), and postherpetic neuralgia (Choi and Rowbotham, 1997). The efficacy of local clonidine in sympathetically maintained pain may result from presynaptic inhibition of NA released from sympathetic nerves as well as actions directly on primary afferent nerve terminals (see above).

Peripheral analgesic actions of clonidine also have been examined following intra-articular injection of clonidine following arthroscopic knee surgery. Both an intrinsic analgesia (Gentili et al., 1996; 1997) and augmentation of analgesia produced by bupivacaine (Reuben and Connelly, 1999; Joshi et al., 2000) and morphine (Buerkle et al., 2000) have been reported. Clonidine has been injected into the inflamed knee joint of rodents in preclinical trials, and analgesia was observed to be enhanced by inflammation (Buerkle et al., 1999). The mechanisms underlying enhanced activity with inflammation are not clear.

H. Adenosine

Both the systemic and spinal administration of adenosine analogs produce antinociception in a range of nociceptive, inflammatory, and neuropathic pain tests in rodents (Sawynok, 1998; Dickenson et al., 2000). In humans, the intravenous infusion of adenosine produces analgesia in experimental pain models in volunteers as well as in acute perioperative pain and chronic neuropathic pain (Segerdahl and Sollevi, 1998). When administered locally to the hindpaw of rats, adenosine A_1 receptor agonists produce analgesia in models of nociceptive pain (Taiwo and Levine, 1990; Aley et al., 1995), inflammatory pain (Karlsten et al., 1992), and neuropathic pain (Liu and Sawynok, 2000). Similarly, local administration of inhibitors of adenosine kinase (that augment local tissue levels of adenosine; Liu et al., 2000a) also produces analgesia in models of inflammatory (Sawynok et al., 1998; McGaraughty et al., 2001) and neuropathic pain (Liu and Sawynok, 2000). The demonstration of a peripheral site of analgesia with adenosine raises the possibility of developing topical formulations of either adenosine A_1 receptor agonists or inhibitors of adenosine kinase as analgesics. Systemic administration of inhibitors of adenosine kinase can also

produce anti-inflammatory actions via adenosine A_{2A} receptors (Kowaluk and Jarvis, 2000), and this occurs due to effects on a variety of peripheral immune cells (Cronstein, 1998). Thus, peripheral adenosine kinase inhibitors might produce a direct effect on pain by actions on the sensory nerve terminal (via A_1 receptors) as well as an indirect effect on the inflammatory process itself (via A_2 receptors). Although potential actions of adenosine on A_{2B} and A_3 receptors on mast cells that produce pain facilitatory effects (Sawynok et al., 1997) could be a limiting factor for inhibitors of adenosine metabolism, these receptors have a lower affinity for adenosine than do adenosine A_1 receptors.

Although peripheral adenosine A_1 receptors hold some appeal as a target for analgesia, several issues need to be resolved regarding their actions. Thus, whereas in rodents adenosine A_1 receptors are implicated in analgesia (see above), in humans pain-initiating actions of adenosine have been attributed to adenosine A_1 receptors (Pappagallo et al., 1993; Gaspardone et al., 1995). In addition, adenosine A_1 receptor agonists increase the firing of sensory afferent nerves (Dowd et al., 1998; Hong et al., 1998; Kirkup et al., 1998), and can cause neurogenic edema following local application in rodents (Sawynok et al., 2000b; Esquisatto et al., 2001).

I. Cannabinoids

Systemic, spinal, and supraspinal administration of cannabinoids can produce analgesia in a variety of nociceptive test systems, and the potential for development of cannabinoids as an alternative class of analgesics is being considered (Rice, 2000; Richardson, 2000; Rice et al., 2002). Cannabinoids can act at peripheral sites to produce analgesia via cannabinoid (CB) CB_1 or CB_2 receptors. Dorsal root ganglia cells that express neuropeptide markers found in nociceptive primary afferents contain mRNA for CB_1 cannabinoid receptors (Hohmann and Herkenham, 1999a), and these receptors are transported both centrally (Hohmann et al., 1999) and peripherally (Hohmann and Herkenham, 1999b). In behavioral experiments, the peripheral administration of agents selective for CB_1 receptors produces a local analgesia in the formalin test (Calignano et al., 1998), the carrageenan hyperalgesia model (Richardson et al., 1998), and the partial nerve injury model (Fox et al., 2001). The peripheral actions of CB_1 receptor agonists are attributed to an effect on the sensory nerve terminal itself to inhibit release of calcitonin gene-related peptide (Richardson et al., 1998) or inhibit sensitizing effects of NGF (Rice et al., 2002). Local analgesic actions of directly and indirectly acting agonists for CB_2 receptors, that are expressed on mast cells and inhibit mast cell function, also have been demonstrated (Calignano et al., 1998; Malan et al., 2001), and CB_2 receptor mechanisms may play a particularly prominent role in inflammatory pain (Rice et al., 2002). Interestingly, coadministration of agonists for both CB_1 and CB_2 receptors produced a

dramatically potentiated analgesia (Calignano et al., 1998). Collectively, such observations raise the possibility of developing local peripheral formulations of cannabinoid derivatives (either alone or as combinations) for pain relief that would be devoid of central actions that currently are of concern for this class of agents.

J. Cholinergic Receptors Agonists

Acetylcholine (ACh) has been known to be a peripheral algogen for some time, but ACh was hardly ever implicated in peripheral pain mechanisms since there was no histological relationship between possible sources of ACh and sensory nerve endings, and extrajunctional ACh levels are low due to choline esterases. However, it now is recognized that peripheral sources of ACh could include sensory neurons themselves (Tata et al., 1994) or keratinocytes and fibroblasts (Grando et al., 1993), and these may release ACh following cutaneous injury. Nicotinic receptors are present on sensory afferent neurons (Boyd et al., 1991; Roberts et al., 1995), and multiple nicotinic receptor subtypes are expressed (Flores et al., 1996; Genzen et al., 2001). ACh can activate sensory afferents through nicotinic receptors (Steen and Reeh, 1993; Jinks and Carstens, 1999; Bernardini et al., 2001), and nicotinic agonists produce sensations of irritation or pain when delivered to skin or the oral mucosa (Dessirier et al., 1997, 1998). Such actions are blocked by specific antagonists and exhibit desensitization with replacement application. Sensory neurons also express multiple muscarinic receptors (Bernardini et al., 1999; Tata et al., 2000), and muscarinic receptor activation, particularly via M2 receptors, results in sensory neuron desensitization (Bernardini et al., 2001, 2002). Thus, selective ligands for certain cholinergic receptors could represent potential peripheral analgesics.

The cholinesterase inhibitor, neostigmine, has been injected directly into the knee joint, and such an approach also provides evidence for a cholinergic peripheral analgesia. Thus, intra-articular neostigmine partially suppresses mechanical hyperalgesia in the rat inflamed knee joint model (Buerkle et al., 1998) and produces some postoperative analgesia in patients undergoing knee surgery (Yang et al., 1998). Although the mechanisms involved in such analgesia were not defined, it could involve desensitization of nociceptors (Bernardini et al., 2001).

K. GABA Agonists

GABA receptors also can modulate peripheral pain signaling. Endogenous peripheral GABA could arise from primary afferent fibers that contain glutamate (which can be converted to GABA by glutamate decarboxylase), and $GABA_A$ receptors are present on some unmyelinated afferent axons (Carlton et al., 1999). In behavioral experiments, local peripheral administration of the $GABA_A$ agonist, muscimol, can initially suppress then, at higher doses, augment the actions of formalin

(Carlton et al., 1999). This is thought to reflect an initial modest primary afferent depolarization that decreases the size of peripheral action potentials and the consequent release of algesic substances, with a subsequent pronounced depolarization of the nerve terminal and initiation of action potentials. On the other hand, activation of $GABA_B$ receptors by local administration of baclofen results in a uniform reduction in formalin-evoked behaviors (Zhou et al., 1998), and these receptors may represent a more promising target than $GABA_A$ receptors.

Gabapentin was originally introduced as a GABA analog, but its action as an anticonvulsant is unrelated to GABA mechanisms (Taylor et al., 1998). Gabapentin, given systemically, is clinically effective in chronic neuropathic pain conditions (Morello et al., 1999; Mao and Chen, 2000). In preclinical studies, systemic and spinal administration of gabapentin produce analgesia in both inflammatory (Field et al., 1997; Shimoyama et al., 1997) and neuropathic pain models (Hunter et al., 1997; Field et al., 1999). The peripheral administration of gabapentin has been reported to produce analgesia by a local action in the formalin test (Carlton and Zhou, 1998). The actions of gabapentin on $GABA_B$ receptors (Bertrand et al., 2001) and on glutamate release (Maneuf et al., 2001) potentially may contribute to local effects.

L. Neuropeptides

Substance P has long been considered an important peptide for the transmission of noxious sensory information, particularly in the dorsal spinal cord. In the periphery, substance P contributes to local axon reflexes and inflammation following release from sensory nerve endings and subsequent mediator release from mast cells, and is a prominent contributor to neurogenic inflammation (Holzer, 1988). Earlier studies noted that substance P did not activate C-fibers to any great extent or sensitize C-fibers to other stimuli using in vitro approaches (Cohen and Perl, 1990; Kessler et al., 1992). Substance P receptors, however, are present on sensory afferent nerve terminals (Carlton et al., 1996), and local injection of substance P into the hindpaw produces hyperalgesia, allodynia and augmentation of the pain-facilitating actions of glutamate (Nakamura-Craig and Gill, 1991; Carlton et al., 1998), which does suggest a contribution to afferent pain signaling by actions on nerve terminals. Substance P also increases vascular permeability, attracts white blood cells, activates phagocytic activity, and increases production and release of inflammatory mediators in neutrophils and macrophages (Levine et al., 1993; Brain, 1996). The peripheral release of substance P may play a role in inflammatory conditions such as arthritis (Levine et al., 1984, 1985). However, clinical trials with nonpeptide neurokinin antagonists have not revealed significant effects on joint pain in arthritis (Rupniak and Hill, 1999; Boyce and Hill, 2000;

Hill, 2000). Given that there is concern about the degree of penetration to central sites of action with neurokinin antagonists, a direct evaluation of the local peripheral actions of substance P antagonists (e.g., by direct injection into the knee joint) may be worthwhile.

Indirect evidence also suggests a significant role of peripheral substance P in nociceptive signaling. Orphinan FQ/nociceptin (OFQ/N) is a recently described peptide that is the endogenous ligand for a cloned orphan opioid receptor (Pasternak, 1998). Local intraplantar administration of low doses of OFQ/N is profoundly nociceptive, and this action is blocked by intraplantar tachykinin antagonists (Inoue et al., 1998). This observation suggests a marked effect of substance P on peripheral pain signaling and a peripheral site for the OFQ/N-substance P interaction, and raises the possibility that antagonists at this receptor may represent a novel peripheral drug target. As at central sites, there is also evidence for dual effects of OFQ/N on sensory neuron function. Thus, like opioids, OFQ/N decreases Ca^{2+} currents in dorsal root ganglion neurons (Abdulla and Smith, 1998) and, given systemically, can inhibit neurogenic inflammation by decreasing the release of substance P and calcitonin gene-related peptide (Helyes et al., 1997; Németh et al., 1998). Such actions could form the basis of a peripherally mediated antinociceptive action for OFQ/N at certain doses and in some conditions, although this has not been demonstrated directly in functional studies.

Other peptides also play a significant role in peripheral pain processing. For example, receptors for somatostatin, which is present in some sensory afferent neurons, are present on peripheral primary afferent sensory fibers, and local peripheral administration of somatostatin reduces nociceptive behaviors induced by formalin and electrophysiological activation of sensory afferents by heat and chemicals (Carlton et al., 2001a). Somatostatin appears to provide a tonic inhibitory effect, as local administration of somatostatin antagonists augments behaviors elicited by formalin and increases nociceptor activity (Carlton et al., 2001b). On the other hand, neuropeptide Y, which is co-released with NA and ATP from sympathetic nerves, can exacerbate hyperalgesia when applied locally to peripheral nerve terminals in a nerve injury model (Tracey et al., 1995b). This effect may be secondary to an action on postganglionic sympathetic nerves. It is likely that the peripheral modulatory influences of neuropeptides on pain signaling are only partially understood at present.

M. Antagonists for Inflammatory Mediators

1. Prostanoids. Inhibition of the production of prostaglandins is a well recognized therapeutic approach, and this forms the basis of the NSAID class of analgesics (*Section III.A.*). An additional strategy involving this class of mediators could be to develop specific antagonists for particular prostanoid receptors. All members of the prostanoid receptor family have been cloned; all are coupled to G-proteins and the pattern of coupling determines the consequences of receptor activation (Coleman et al., 1994). In situ hybridization studies reveal the presence of mRNA for multiple prostanoid receptors in dorsal root ganglion neurons (Sugimoto et al., 1994; Oida et al., 1995). The major effect of prostanoids on sensory afferents is to sensitize these to the actions of chemicals, heat, and mechanical stimuli, and prostaglandin E_2, prostacyclin I_2, leukotriene B_4, and leukotriene D_4 exhibit the more prominent roles in this regard (Bevan, 1999; Raja et al., 1999). Whereas antagonism of prostanoid receptors remains a potential therapeutic strategy, only a limited number of such agents are presently available (Rang et al., 1999).

2. Bradykinin. Activation of bradykinin B_2 receptors on sensory nerves produces pain and hyperalgesia by depolarization and sensitization of nerve fibers to physical stimuli (heat and mechanical), whereas activation of B_2 receptors on other tissues such as sympathetic nerves and inflammatory cells stimulates the production of proinflammatory mediators such as prostanoids and cytokines (Dray, 1997). The B_1 receptor, for which the major metabolite of bradykinin des-Arg^9-bradykinin has a greater affinity than the parent peptide, is expressed under inflammatory conditions and plays a prominent role in inflammatory hyperalgesia by actions on targets other than sensory nerves (Dray and Perkins, 1993; Davis et al., 1996). The involvement of both B_1 and B_2 receptors in inflammatory hyperalgesia suggests that kinin antagonists might be useful analgesics in such conditons. Both peptidic and nonpeptidic B_1 and B_2 antagonists have been developed (Hall, 1992; Dray and Urban, 1996). Peptidic antagonists have been available for some time, but the focus for drug development primarily has been on the development of orally active nonpeptide antagonists (e.g., Asano et al., 1997). Given that central activation of B_2 receptors also may contribute to pain (Dray, 1997), systemic antagonists may have the advantage of multiple sites of action. However, the possibility of topical application of nonpeptidic B_1 and B_2 antagonists could be considered, because such preparations could potentially avoid adverse effects at central sites or in tissues other than the one in which the pain primarily originates.

3. ATP. The ability of local peripheral administration of ATP to elicit pain in humans has been known for some time (Bleehen and Keele, 1977), but it is only in the last few years that the receptors and mechanisms underlying this response have been understood. The excitatory effects of ATP on sensory neurons are now known to be mediated by $P2X_3$ ligand-gated cation channels (Chen et al., 1995; Lewis et al., 1995). This receptor is selectively expressed in capsaicin-sensitive C-fibers, and heteromeric forms ($P2X_2/P2X_3$) can mimic the action of the native receptor (Jarvis and Kowaluk, 2001). ATP may play an important role in pain signaling in inflam-

mation and following nerve injury (Bland-Ward and Humphrey, 2000; Burnstock, 2000; Hamilton and McMahon, 2000). In behavioral studies, local administration of ATP and its analogs produces overt pain behaviors (Bland-Ward and Humphrey, 1997) that are enhanced by inflammation (Sawynok and Reid, 1997; Hamilton et al., 1999, 2000), as well as mechanical allodynia (Tsuda et al., 2000). Following nerve injury, $P2X_3$ receptors are up-regulated in dorsal root ganglia and the dorsal spinal cord (Novakovic et al., 1999; Tsuzuki et al., 2001). ATP increases firing of Aβ-afferent fibers (Chen et al., 2001), enhances the activity of units showing ectopic activity (Zhou et al., 2001a), and interacts with the sympathetic nervous system following nerve injury (Park et al., 2000). Collectively, the above observations indicate that peripheral ATP receptors on both capsaicin-sensitive and capsaicin-insensitive neurons may mediate elements of inflammatory and neuropathic pain by actions on $P2X_3$ and $P2X_{2/3}$ heteromers. This raises the possibility that antagonists selective for these receptors might be useful as peripherally acting or topical analgesics (Jarvis and Kowaluk, 2001).

4. Biogenic Amines. 5-HT is contained in platelets, and in several species (although not humans), in cutaneous mast cells. 5-HT produces pain when applied to the human blister base and is a well recognized algogen (Richardson et al., 1985). Applied peripherally to rodents, 5-HT produces spontaneous pain behaviors and hyperalgesia, particularly when combined with other inflammatory mediators such as prostaglandin E_2, bradykinin, NA, and histamine (Taiwo and Levine, 1992; Hong and Abbott, 1994; Abbott et al., 1996) or injected in combination with a low concentration of formalin (Doak and Sawynok, 1997). There is considerable electrophysiological data supporting both excitation and sensitization of nociceptive afferents by 5-HT (Kress and Reeh, 1996). Peripheral 5-HT actions are due to activation of ligand-gated cation channels via $5-HT_3$ receptors (Richardson et al., 1985) as well as via $5-HT_1$, $5-HT_2$, and $5-HT_4$ receptors that exert effects through G-protein-coupled receptors (Taiwo and Levine, 1992; Abbott et al., 1996; Doak and Sawynok, 1997). The local peripheral administration of antagonists selective for several of these receptors reduces pain elicited by inflammatory mediators and inflammation (Giordano and Roberts, 1989; Abbott et al., 1996, 1997; Doak and Sawynok, 1997; Parada et al., 2001). Such observations indicate that local formulations of 5-HT antagonists may be a potentially useful approach for inflammatory pain. In humans, topical odansetron, a selective $5-HT_3$ receptor antagonist, reduces pain elicited by intradermal capsaicin (Giordano et al., 1998) providing direct support for this concept. Peripheral analgesia by $5-HT_3$ receptor antagonists can be augmented by combination with other 5-HT receptor antagonists (Espejo and Gil, 1998), or subanesthetic doses of local anesthetics (Giordano and Sacks, 1997), indicating that combination strategies

involving this class of agents might be worthy of further attention.

Histamine originates from storage granules in mast cells and basophilic leukocytes that infiltrate inflamed tissue from blood. The most prominent local action of histamine in skin is itch, reflecting a direct action on sensory nerves, as well as wheal, reddening, and extravasation due to vasodilation; there is a further and more widespread flare response due to an axon reflex or neurogenic inflammation (Simone et al., 1987). Histamine alone produces some activation of sensory afferents, but more prominently, it sensitizes the nerve terminal to the action of other inflammatory mediators (Hong and Abbott, 1994; Carstens, 1997). These stimulatory actions are due to activation of histamine H_1 receptors on the sensory nerve, which produces an increase in membrane Ca^{2+} permeability (Ninkovic and Hunt, 1985); further actions may occur secondarily to the release of peptides from sensory afferent terminals (Saria et al., 1988). In rodent models, the local peripheral application of antagonists for histamine H_1 receptors produces analgesic responses in the formalin test (Sawynok et al., 2000a; Parada et al., 2001).

In humans, when itch is a prominent complaint, topical antihistamine preparations such as doxepin (a tricyclic antidepressant with prominent histamine blocking actions) have been used to control the itch (Drake et al., 1995; Smith and Corelli, 1997). As noted above (*Section III.E.*), topical doxepin can also relieve neuropathic pain (McCleane, 2000a,b). This raises the possibility that antihistaminic actions of antidepressants may contribute to analgesia by this class of agents. However, itch and pain appear to be distinct sensations (McMahon and Koltzenburg, 1992; Carstens, 1997), such that the extent to which antihistaminic actions account for the peripheral analgesic action of antidepressants is not clear (Sawynok et al., 2000a).

5. Nerve growth factor. NGF is a target-derived survival factor that plays an important role in development and plays a critical role in the regulation of sensory neuron properties in inflammatory and neuropathic states in adult animals (Lewin, 1995; McMahon and Priestley, 1995; McMahon and Bennett, 1999). NGF sensitivity can distinguish particular subsets of sensory neurons, regulate peptide, ion channel, and growth factor expression in such neurons (McMahon and Bennett, 1999; Gould et al., 2000). NGF involvement in inflammatory and neuropathic pain differs, and deficits can result not only from a neurotropin excess but also from a deficiency.

During inflammation, tissue levels of NGF are increased, and the administration of anti-NGF antibodies reduces inflammatory hypersensitivity (Donnerer et al., 1992; Woolf et al., 1994). Peripheral actions of NGF on sensory neurons, mast cells, and sympathetic efferents (transiently) contribute to the hyperalgesia (Woolf et al., 1996). Central actions, mediated by changes in the ex-

pression of neuropeptides, ion channels, and growth factors in the sensory neurons, contribute to later manifestations (Donnerer et al., 1992; Leslie et al., 1995; Michael et al., 1997). Although drugs that inhibit the actions of NGF (e.g., antibodies, fusion proteins) may be useful for the treatment of chronic inflammatory pain, large proteins are likely to be of limited use systemically (Rang et al., 1999). Whereas topical or local delivery forms of simpler molecules that inhibit NGF actions (e.g., ALE-0540; Owolabi et al., 1999) may selectively target peripheral components of action and minimize actions at central sites, NGF exerts actions at multiple peripheral targets (e.g., mast cells, eosinophils, T-, and B-cells; McMahon and Bennett, 1999). It is unclear if such an agent would have the required target specificity to be an effective analgesic agent.

In contrast to inflammatory pain, neuropathic pain may benefit from the augmentation of NGF. Thus, following nerve injury, sensory neurons become disconnected from their targets and the supply of NGF is reduced; this leads to a compensatory response in which non-neuronal cells now produce NGF, and the NGF now exerts neuroprotective effects on the sensory neuron (McMahon and Bennett, 1999). In functional studies, NGF can ameliorate adverse effects on neural function induced by streptozotocin and cytostatic drugs and nerve injury in rodent models (McMahon and Priestley, 1995; Ren et al., 1995). In humans, recombinant human NGF has been demonstrated to improve chemotherapy-induced neuropathies (Apfel et al., 1992), diabetic neuropathy (Apfel et al., 1998), and human immunodeficiency virus-associated sensory neuropathy (McArthur et al., 2000). On the other hand, there are reports that NGF regulates sympathetic sprouting into dorsal root ganglia and contributes to sympathetically maintained pain (Ramer et al., 1999) and, when applied to dorsal root ganglia, triggers a persistent allodynia (Zhou et al., 2000b). In addition, a novel nonpeptide NGF antagonist has an anti-allodynic action in a spinal nerve ligation model (Owolabi et al., 1999). Such observations suggest that *block* of NGF activity might be useful in alleviating manifestations of neuropathic pain. Further study is required, particularly because it is recognized that actions of NGF on behaviors can be complex, reflecting both central and peripheral actions (Lewin et al., 1994; Lewin, 1995), early and delayed responses (Ro et al., 1999), and can depend on the location of the nerve injury (Ramer and Bisby, 1999). Similarly, the role of regulation of NGF actions that remain limited to peripheral actions by localized delivery methods remains to be determined.

IV. Conclusions

Peripheral pain signaling in conditions of chronic pain involving inflammation and nerve injury can involve the actions of a complex array of chemical mediators that impinge upon the sensory nerve. This can reflect direct actions on the sensory nerve, or indirect actions on sites adjacent to the sensory nerve. Inflammatory pain, in particular, involves the actions of multiple peripheral mediators that frequently interact with each other to produce a more pronounced activation of the sensory nerve terminal (sensitization, facilitation). The success of a strategy that targets a particular mediator will depend on the overall contribution of that mediator to pain signaling in relation to other mediators. Thus, the success of the therapeutic strategy of inhibiting the production of prostaglandins, which are only one class of pain facilitators, may reside in their ability to sensitize nerve endings to multiple mediators, as well as to actions at multiple steps in the complex cascade of inflammatory pain (e.g., release from adjacent structures by other mediators). For neuropathic pain, peripheral pain signaling mechanisms involving hyperexcitability/spontaneous activity of afferents is also an important contributor to pain. In this instance, there may be a differential involvement of particular peripheral mediators compared with chronic inflammation, with certain elements that have been perturbed playing a particularly prominent role. Considerations in the body of this review indicate that both inflammation and nerve injury pain are amenable to modulation by the peripheral application of drugs, such that both conditions potentially can benefit from the topical application or localized application of appropriate agents for the relief of pain. The success of a particular strategy in a particular condition may reflect the degree of involvement of inflammatory versus neurogenic components. Although these are not mutually exclusive categories, it may be that some treatments are more effective for certain conditions than others. For example, NSAIDs or other strategies that primarily target inflammation may have limited efficacy in nerve injury pain, and the latter condition may be more amenable to drugs that act directly on the sensory nerve to dampen down sensory afferent nerve activity.

The above review has focused on specific targets and classes of drugs. In recognizing the chemical complexity of pain signaling, it is important to appreciate that optimal pain relief may require combinations of more than one agent. Thus, although individual treatment strategies may give significant pain relief, this still may be only partial and require the addition of another ingredient for a more complete effect. With inflammatory pain, combinations could include any number of multiple targets for inflammatory mediators. With neuropathic pain, there are again examples of agents that can act peripherally to regulate pain expression. An interesting aspect of such combinations would be agents that target mechanisms on C-fibers as well as Aβ-fibers, because this would provide a more complete spectrum of pain relief. Finally, if tolerance occurs to repeated peripheral application of analgesics (as shown for opioids), then combination strategies might target a suppression of

mechanisms involved in tolerance (e.g., NMDA receptor antagonists with opioids). Thus, as topical formulations of drugs are developed, it is clear that certain combinations may be useful to develop as well. With the potential for fewer systemic adverse drug effects and drug interactions, topical formulations of analgesics for chronic pain conditions represent a promising area for future drug development.

References

Abbott FV, Hong Y, and Blier P (1996) Activation of 5-HT$_{2A}$ receptors potentiates pain produced by inflammatory mediators. *Neuropharmacology* **35:**99–110.

Abbott FV, Hong Y, and Blier P (1997) Persisting sensitization of the behavioural response to formalin-induced injury in the rat through activation of serotonin$_{2A}$ receptors. *Neurosci* **77:**575–584.

Abdulla FA and Smith PA (1998) Axotomy reduces the effect of analgesic opioids yet increases the effect of nociceptin on dorsal root ganglion neurons. *J Neurosci* **18:**9685–9694.

Aley KO, Green PG, and Levine JD (1995) Opioid and adenosine peripheral antinociception are subject to tolerance and withdrawal. *J Neurosci* **15:**8031–8038.

Aley KO and Levine JD (1997a) Multiple receptors involved in peripheral α_2, μ, and A$_1$ antinociception, tolerance and withdrawal. *J Neurosci* **17:**735–744.

Aley KO and Levine JD (1997b) Dissociation of tolerance and dependence for opioid peripheral antinociception in rats. *J Neurosci* **17:**3907–3912.

Ali Z, Raja SN, Wesselmann U, Fuchs PN, Meyer RA, and Campbell JN (2000) Intradermal injection of norepinephrine evokes pain in patients with sympathetically maintained pain. *Pain* **88:**161–168.

Antonijevic I, Mousa SA, Schäfer M, and Stein C (1995) Perineurial defect and peripheral opioid analgesia in inflammation. *J Neurosci* **15:**165–172.

Apfel SC, Arezzo JC, Lipson L, and Kessler JA (1992) Nerve growth factor prevents experimental cisplatin neuropathy. *Ann Neurol* **31:**76–80.

Apfel SC, Kessler JA, Adornato BT, Litchy WJ, Sanders C, and Rask CA (1998) Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. *Neurology* **51:**695–702.

Asano M, Inamura N, Hatori C, Sawai H, Fujiwara T, Katayama A, Kayakiri H, Satoh S, Abe Y, Inoue T, et al. (1997) The identification of an orally active, nonpeptide bradykinin B$_2$ receptor antagonist, FR173657. *Br J Pharmacol* **120:**617–624.

Attal N and Bouhassira D (1999) Mechanisms of pain in painful neuropathy. *Acta Neurol Scand* **173:**12–24.

Attal N, Brasseur L, Chauvin M, and Bouhassira D (1999) Effects of single and repeated applications of a eutectic mixture of local anaesthetics (EMLA^R) cream on spontaneous and evoked pain in post-rtpetic neuralgia. *Pain* **81:**203–209.

Bach FW, Jensen TS, Kastrup J, Stigsby B, and Dejgard A (1990) The effect of intravenous lidocaine on nociceptive processing in diabetic neuropathy. *Pain* **40:**29–34.

Back IN and Finlay I (1995) Analgesic effect of topical opioids on painful skin ulcers. *J Pain Symptom Manage* **10:**493.

Ballas SK (2002) Treatment of painful sickle cell leg ulcers with topical opioids. *Blood* **99:**1096.

Baron R (2000) Peripheral neuropathic pain: from mechanisms to symptoms. *Clin J Pain* **16:**S12–S20.

Basbaum AI and Fields HL (1984) Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. *Ann Rev Neurosci* **7:**309–338.

Bayas-Smith MG, Max MB, Muir J, and Kingman A (1995) Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage 'enriched enrollment' design. *Pain* **60:**267–274.

Bernardini N, Levey AI, and Augusti-Tocco G (1999) Rat dorsal root ganglia express m1–m4 muscarinic receptor proteins. *J Peripher Nerv Sys* **4:**222–232.

Bernardini N, Roza C, Aauer SK, Gomeza J, Wess J, and Reeh PW (2002) Muscarinic M2 receptors on peripheral nerve endings: a molecular target of antinociception. *J Neurosci* **22 (RC229):**1–5.

Bernardini N, Sauer SK, Harberberger R, Fischer MJM, and Reeh PW (2001) Excitatory nicotinic and desensitizing muscarinic (M2) effects on C-nociceptors in isolated rat skin. *J Neurosci* **21:**3295–3302.

Bernstein JE, Korman NJ, Bickers DR, Dahl MV, and Millikan LE (1989) Topical capsaicin treatment of chronic postherpetic neuralgia. *J Am Acad Dermatol* **21:**265–270.

Bertrand S, Ng GYK, Purisai MG, Wolfe SE, Severidt MW, Nouel D, Robitaille R, Low MJ, O'Neill GP, Metters K, et al. (2001) The anticonvulsant, antihyperalgesic agent gabapentin is an agonist at brain γ-aminobutryric acid type B receptors negatively coupled to voltage-dependent calcium channels. *J Pharmacol Exp Ther* **298:**15–24.

Besson JM and Chaouch A (1987) Peripheral and spinal mechanisms of nociception. *Physiol Rev* **67:**67–186.

Bevan S (1999) Nociceptive peripheral neurons: cellular properties, in *Textbook of Pain* (Wall PD and Melzack R eds) 4th ed, pp 85–103, Churchill-Livingstone, Edinburgh.

Bhave G, Karim F, Carlton SM, and Fereau RW (2001) Peripheral group I metabotropic glutamate receptors modulate nociception in mice. *Nat Neurosci* **4:**417–423.

Birder LA and Perl ER (1999) Expression of α_2-adrenergic receptors in rat primary afferent neurones after peripheral nerve injury or inflammation. *J Physiol (Lond)* **515:**533–542.

Bland-Ward PA and Humphrey PPA (1997) Acute nociception mediated by hindpaw P2X receptor activation in the rat. *Br J Pharmacol* **122:**365–371.

Bland-Ward PA and Humphrey PPA (2000) P2X receptors mediate ATP-induced primary nociceptive neurone activation. *J Auton Nerv Sys* **81:**146–151.

Bleehen T and Keele CA (1977) Observations on the algogenic actions of adenosine compounds on human blister base preparation. *Pain* **3:**367–377.

Bowersox SS, Gadbois T, Singh T, Pettus M, Wang YX, and Luther RR (1996) Selective N-type neuronal voltage-sensitive calcium channel blocker, SNX-111, produces spinal antinociception in rat models of acute, persistent and neuropathic pain. *J Pharmacol Exp Ther* **279:**1243–1249.

Boyce S and Hill RG (2000) Discrepant results form preclinical and clinical studies on the potential of substance P-receptor antagonist compounds as analgesics, in *Proceedings of the 9th World*, *Congress on Pain, Progress in Pain Research and Management* (Devor M, Rowbotham MC and Weisenfeld-Hallin Z eds) vol 16, pp 313–324, IASP Press, Seattle.

Boyd RT, Jacob MH, McEachern AE, Caron S, and Berg DK (1991) Nicotinic acetylcholine receptor mRNA in dorsal root ganglion neurons. *J Neurobiol* **22:**1–14.

Brain SD (1996) Sensory neuropeptides in the skin, in *Neurogenic Inflammation* (Gepetti P and Holzer P, eds), pp 229–244, CRC Press, Boca Raton, FL

Bridges D, Thompson SWN, and Rice ASC (2001) Mechanisms of neuropathic pain. *Br J Anaesth* **87:**12–26.

Buerkle H (1999) Intraarticular "analgesics": are they safe? *Anesth Analg* **89:**802–803.

Buerkle H, Boschin M, Marcus MAE, Brodner G, Wüsten R, and Van Aken H (1998) Central and peripheral analgesia mediated by the acetylcholinesterase inhibitor neostigmine in the rat inflamed knee joint model. *Anesth Analg* **86:**1027–1032.

Buerkle H, Huge V, Wolfgart M, Steinbeck J, Mertes N, Van Aken H, and Prien T (2000) Intra-articular clonidine analgesia after knee arthroscopy. *Eur J Anaesthesiol* **17:**295–299.

Buerkle H, Schäpsmeier M, Bantel C, Marcus MAE, Wüsten R, and Van Aken H (1999) Thermal and mechanical antinociceptive action of spinal vs peripherally administered clonidine in the rat inflamed knee joint model. *Br J Anaesth* **83:**436–441.

Burnstock G (2000) P2X receptors in sensory neurones. *Br J Anaesth* **84:**476–488.

Calignano A, La Rana G, Giuffrida A, and Piomelli D (1998) Control of pain initiation by endogenous cannabinoids. *Nature (Lond)* **394:**277–281.

Capsaicin Study Group (1992) Effect of treatment with capsaicin on daily activities of patients with painful diabetic neuropathy. *Diabetes Care* **15:**159–165.

Carlton SM (2001) Peripheral excitatory amino acids. *Curr Opin Pharmacol* **1:**52–56.

Carlton SM and Coggeshall RE (1999) Inflammation-induced changes in peripheral glutamate receptor populations. *Brain Res* **820:**63–70.

Carlton SM, Du J, Davidson E, Zhou S, and Coggeshall RE (2001a) Somatostatin receptors on peripheral primary afferent terminals: inhibition of sensitized nociceptors. *Pain* **90:**233–244.

Carlton SM, Du J, Zhou S, and Coggeshall RE (2001b) Tonic control of peripheral cutaneous nociceptors by somatostatin receptors. *J Neurosci* **21:**4042–4049.

Carlton SM, Hargett GL, and Coggeshall RE (1995) Localization and activation of glutamate receptors in unmyelinated axons of rat glabrous skin. *Neurosci Lett* **197:**25–28.

Carlton SM and Zhou S (1998) Attenuation of formalin-induced nociceptive behaviors following local peripheral injection of gabapentin. *Pain* **76:**201–207.

Carlton SM, Zhou S, and Coggeshall RE (1996) Localization and activation of substance P receptors in unmyelinated axons of rat glabrous skin. *Brain Res* **734:**103–108.

Carlton SM, Zhou S, and Coggeshall RE (1998) Evidence for the interaction of glutamate and NK1 receptors in the periphery. *Brain Res* **790:**160–169.

Carlton SM, Zhou S, and Coggeshall RE (1999) Peripheral GABA$_A$ receptors: evidence for peripheral primary afferent depolarization. *Neuroscience* **93:**713–722.

Carstens E (1997) Responses of rat spinal dorsal horn neurons to intracutaneous microinjection of histamine, capsaicin and other irritants. *J Neurophysiol* **77:**2499–2514.

Carter RB and Francis WR (1991) Capsaicin desensitization to plasma extravasation by antidromic C-fibre stimulation is not assoicated with antinociception in the rat. *Neurosci Lett* **127:**49–52.

Caterina MJ and Julius D (1999) Sense and specificity: a molecular identity for nociceptors. *Curr Opin Neurobiol* **9:**525–530.

Caterina MJ and Julius D (2001) The vanilloid receptor: a molecular gateway to the pain pathway. *Annu Rev Neurosci* **24:**487–517.

Caterina MJ, Schumacher MA, Tominga M, Rosen TA, Levine JD, and Julius D (1997) The capsaicin receptor: a heat-activated ion channel in the pain pathway. *Nature (Lond)* **389:**816–824.

Catterall WA (2000) From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. *Neuron* **26:**13–25.

Chabal C, Jacobson L, Mariano A, Chaney E, and Brittell CW (1992) The use of oral mexiletine for the treatment of pain after peripheral nerve injury. *Anesthesiology* **76:**513–517.

Chandrasekharan NV, Dai H, Roos KLT, Evanson NK, Tomsik J, Elton TS, and Simmons DL (2002) COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs. Cloning, structure and expression. *Proc Natl Acad Sci USA* **99:**13926–13931.

Chaplan SR, Pogrel JW, and Yaksh TL (1994) Role of voltage-dependent calcium channel subtypes in experimental tactile allodynia. *J Pharmacol Exp Ther* **269:**1117–1123.

Chen CC, Akoplan AN, Sivilotti L, Colquhoun D, Burnstock G, and Wood JN (1995) A P2X purinoceptor expressed by a subset of sensory neurons. *Nature (Lond)* **377:**428–431.

Chen Y, Michaelis M, Jänig W, and Devor M (1996) Adrenoreceptor subtype medi-

ating sympathetic-sensory coupling in injured sensory neurons. *J Neurophysiol* **76:**3721–3730.

Chen Y, Zhang YH, and Zhao ZQ (2001) Novel purinergic sensitivity develops in injured sensory axons following sciatic nerve transection in rat. *Brain Res* **911:**168–172.

Cho HJ, Kim DS, Lee NH, Kim JK, Lee KM, Han KS, Kang YN, and Kim KJ (1997) Changes in the α_2-adrenergic receptor subtypes gene expression in rat dorsal root ganglion in an experimental model of neuropathic pain. *Neuroreport* **8:**3119–3122.

Choi B and Rowbotham MC (1997) Effect of adrenergic receptor activation on post-herpetic neuralgia pain and sensory disturbances. *Pain* **69:**55–63.

Coderre TJ (1999) Excitatory amino acid antagonists: potential analgesics for persistent pain, in *Novel Aspects of Pain Management: Opioids and Beyond* (Sawynok J and Cowan A eds) pp 157–178, Wiley-Liss, New York.

Coderre TJ, Katz J, Vaccarino A, and Melzack R (1993) Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. *Pain* **52:**259–285.

Coggeshall RE and Carlton SM (1997) Receptor localization in the mammalian dorsal horn and primary afferent neurons. *Brain Res Rev* **24:**28–66.

Coggeshall RE and Carlton SM (1999) Evidence for an inflammation-induced change in the local glutamatergic regulation of postganglionic sympathetic efferents. *Pain* **83:**163–168.

Coggeshall RE, Zhou S, and Carlton SM (1997) Opioid receptors on peripheral sensory axons. *Brain Res* **764:**126–132.

Cohen RH and Perl ER (1990) Contributions of arachidonic acid derivatives and substance P to the sensitization of cutaneous nociceptors. *J Neurophysiol* **64:**457–464.

Coleman RA, Smith WL, and Navumiya S (1994) International Union of Pharmacology classification of prostanoid receptors: properties, distribution and structure of the receptors and their subtypes. *Pharm Rev* **46:**205–229.

Cronstein BN (1998) Adenosine and its receptors during inflammation, in *Molecular and Cellular Basis of Inflammation* (Serhan CN and Ward PA, eds) pp 259–274, Humana Press, Totowa, NJ.

Crowley KL, Flores JA, Hughes CN, and Iacono RP (1998) Clinical application of ketamine ointment in the treatment of sympathetically maintained pain. *Int J Pharmaceutical Compounding* **2:**122–127.

Dado RJ, Law PY, Loh HH, and Elde R (1993) Immunoflourescent identification of a delta (δ)-opioid receptor on primary afferent nerve terminals. *Neuroreport* **5:**341–344.

Davidson EM and Carlton SM (1998) Intraplantar injection of dextromethorphan, ketamine or memantine attenuates formalin-induced behaviors. *Brain Res* **785:**136–142.

Davidson EM, Coggeshall RE, and Carlton SM (1997) Peripheral NMDA and non-NMDA glutamate receptors contribute to nociceptive behaviors in the rat formalin test. *Neuroreport* **8:**941–946.

Davis CL, Naemm S, Phagoo SB, Campbell EA, Urban L, and Burgess GN (1996) B$_1$ bradykinin receptors and sensory neurones. *Br J Pharmacol* **118:**1469–1476.

Davis KD, Treede RD, Raja SN, Meyer RA, and Campbell JN (1991) Topical application of clonidine relieves hyperalgesia in patients with sympathetically maintained pain. *Pain* **47:**309–317.

deGroot J, Zhou S, and Carlton SM (2000) Peripheral glutamate release in the hindpaw following low and high intensity sciatic stimulation. *Neuroreport* **11:**497–502.

Dejgard A, Petersen P, and Kastrup J (1988) Mexilitine for treatment of chronic painful diabetic neuropathy. *Lancet* **1:**9–11.

Dessirier JM, O'Mahony M, and Carstens E (1997) Oral irritant effects of nicotine: psychophysical evidence for decreased sensation following repeated application and lack of cross-desensitization with capsaicin. *Chem Senses* **22:**483–492.

Dessirier JM, O'Mahony M, Sieffermann JM, and Carstens E (1998) Mecamylamine inhibits nicotine but not capsaicin irritation on the tongue: psychophysical evidence that nicotine and capsaicin activate separate molecular receptors. *Neurosci Lett* **240:**65–68.

Devers A and Galer BS (2000) Topical lidocaine patch relieves a variety of neuropathic pain conditions: an open-label study. *Clin J Pain* **16:**205–208.

Devor M and Seltzer Z (1999) Pathophysiology of damaged nerves in relation to chronic pain, in *Textbook of Pain* (Wall PD and Melzack R eds) 4th ed, pp 79–100, Churchill Livingstone, Edinburgh.

Dickenson AH (1994) NMDA receptor antagonists as analgesics, in *Progress in Pain Research and Management* (Fields HL and Liebskind JC eds) pp 173–187, IASP Press, Seattle.

Dickenson AH, Chapman V, and Green GM (1997) The pharmacology of excitatory and inhibitory amino acid-mediated events in the transmission and modulation of pain in the spinal cord. *Gen Pharmacol* **28:**633–638.

Dickenson AH, Suzuki R, and Reeve AJ (2000) Adenosine as a potential analgesic target in inflammatory and neuropathic pains. *CNS Drugs* **13:**77–85.

Dini D, Bertelli G, Gozza A, and Forno GG (1993) Treatment of the post-mastectomy pain syndrome with topical capsaicin. *Pain* **54:**223–226.

Doak GJ and Sawynok J (1997) Formalin-induced nociceptive behavior and edema: involvement of multiple peripheral 5-hydroxytryptamine receptor subtypes. *Neuroscience* **80:**939–949.

Docherty RJ, Robertson B, and Bevan S (1991) Capsaicin causes prolonged inhibition of voltage-activated calcium currents in adult rat dorsal root ganglion neurons in culture. *Neuroscience* **40:**513–521.

Donnerer J, Schuligoi R, and Stein C (1992) Increased content and transport of substance P and calcitonin gene-related peptide in sensory nerves innervating inflamed tissue: evidence for a regulatory function of nerve growth factor in vivo. *Neuroscience* **49:**693–698.

Doubell TP, Mannion RJ, and Woolf CJ (1999) The dorsal horn: state dependent sensory processing, plasticity and the generation of pain, in *Textbook of Pain* (Wall PD, Melzack R eds) 4th ed, pp 165–181, Churchill Livingstone, Edinburgh.

Dowd E, McQueen DS, Chessell IP, and Humphrey PPA (1998) Adenosine A$_1$-receptor-mediated excitation of nociceptive afferents innervating the normal and arthritic rat knee joint. *Br J Pharmacol* **125:**1267–1271.

Drake LA, Millikan LE, and Doxepin Study Group (1995) The antipruritic effect of 5% doxepin cream in patients with eczematous dermatitis. *Arch Dermatol* **131:**1403–1408.

Dray A (1997) Kinins and their receptors in hyperalgesia. *Can J Physiol Pharmacol* **75:**704–712.

Dray A and Perkins M (1993) Bradykinin and inflammatory pain. *Trends Neurosci* **16:**99–104.

Dray A and Urban L (1996) New pharmacological strategies for pain relief. *Annu Rev Pharmacol Toxicol* **36:**253–280.

Duman RS, Heninger GR, and Nestler EJ (1997) A molecular and cellular theory of depression. *Arch Gen Psychiat* **54:**597–606.

Edwards WT, Habib F, Burney RG, and Begin G (1985) Intravenous lidocaine in the management of various chronic pain states. A review of 211 cases. *Reg Anesth* **10:**1–6.

Epstein JB, Grushka M, and Le N (1997) Topical clonidine for orofacial pain: a pilot study. *J Orofac Pain* **11:**346–352.

Epstein JB and Marcoe JH (1994) Topical capsaicin for treatment of oral neuropathic pain and trigeminal neuralgia. *Oral Surg Oral Med Oral Pathol* **77:**135–140.

Epstein JB, Truelove EL, Oien H, Allison C, Le ND, and Epstein MS (2001) Oral topical doxepin rinse: analgesic effect in patients with oral mucosal pain due to cancer or cancer therapy. *Oral Oncol* **37:**632–637.

Eschalier A, Ardid D, and Dubray C (1999) Tricyclic and other antidepressants as analgesics, in *Novel Aspects of Pain Management: Opioids and Beyond* (Sawynok J and Cowan A eds), pp 303–310, Wiley-Liss, New York.

Espejo EF and Gil E (1998) Antagonism of peripheral 5-HT$_4$ receptors reduces visceral and cutaneous pain in mice and induces visceral analgesia after simultaneous inactivation of 5-HT$_3$ receptors. *Brain Res* **788:**20–24.

Esquisatto LCM, Costa SKP, Camargo EA, Ribela MTCP, Braion SD, de Nucci G, and Antunes E (2001) The plasma protein extravasation induced by adenosine and its analogues in the rat dorsal skin: evidence for the involvement of capsaicin sensitive primary afferent neurones and mast cells. *Br J Pharmacol* **134:**108–115.

Esser MJ and Sawynok J (1999) Acute amitriptyline in a rat model of neuropathic pain: differential symptom and route effects. *Pain* **80:**643–653.

Esser MJ and Sawynok J (2000) Caffeine blockade of the thermal anti-hyperalgesic effect of acute amitriptyline in a rat model of neuropathic pain. *Eur J Pharmacol* **399:**131–139.

Field MJ, McCleary S, Hughes J, and Singh L (1999) Gabapentin and pregabali, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat. *Pain* **80:**391–398.

Field MJ, Oles RJ, Lewis AS, McCleary S, Hughes J, and Singh L (1997) Gabapentin (neurontin) and S-(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents. *Br J Pharmacol* **121:**1513–1522.

Fields HL and Basbaum AI (1994) Central nervous system mechanisms of pain modulation, in *Textbook of Pain* (Wall PD and Melzack R, eds) 3rd ed, pp 243–257, Churchill-Livingstone, Edinburgh.

Fields HL, Rowbotham MC, and Devor M (1997) Excitability blockers: anticonvulsants and low concentration local anesthetics in the treatment of chronic pain, in *Handbook of Experimental Pharmacology, The Pharmacology of Pain* (Dickenson A and Besson JM eds) vol 130, pp 93–116, Springer-Verlag, Berlin.

Fisher K, Coderre TJ, and Hagen NA (2000) Targeting the N-methyl-D-aspartate receptor for chronic pain management: preclinical animal studies, recent clinical experience and future research directions. *J Pain Symptom Manage* **20:**358–373.

Flores CM, DeCamp RM, Kilo S, Rogers SW, and Hargreaves KM (1996) Neuronal nicotinic receptor expression in sensory neurons of the rat trigeminal ganglion: demonstration of α3β4, a novel subtype in the mammalian nervous system. *J Neurosci* **16:**7892–7901.

Fox A, Kesingland A, Gentry C, McNair K, Patel S, Urban L, and James I (2001) The role of central and peripheral cannabinoid$_1$ receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. *Pain* **92:**91–100.

Fuchs PN, Pappagallo M, and Meyer RA (1999) Topical EMLA^R pre-treatment fails to decrease the pain induced by 1% topical capsaicin. *Pain* **80:**637–642.

Galer BS, Harle J, and Rowbotham MC (1996) Response to intravenous lidocaine infusion predicts subsequent response to oral mexilitine: a prospective study. *J Pain Symptom Manage* **12:**161–167.

Galer BS, Miller KV, and Rowbotham MC (1993) Response to intravenous lidocaine infusion differs based on clinical diagnosis and site of nervous system injury. *Neurology* **43:**1233–1235.

Galer BS, Rowbotham MC, Perander J, Devers A, and Friedman E (2000) Topical diclofenac patch relieves minor sports injury pain: results of a multicenter controlled clinical trial. *J Pain Symptom Manage* **19:**287–294.

Galer BS, Rowbotham MC, Perander J, and Friedman E (1999) Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. *Pain* **80:**533–538.

Gaspardone A, Crea F, Tomai F, Versaci F, Iamele M, Gioffrè G, Chiariello L, and Gioffrè PA (1995) Muscular and cardiac adenosine-induced pain is mediated by A$_1$ receptors. *J Am Coll Cardiol* **25:**251–257.

Gentili M, Houssel P, Osman M, Henel D, Juhel A, and Bonnet F (1997) Intra-articular morphine and clonidine produce comparable analgesia but the combination is not more effective. *Br J Anaesth* **79:**660–661.

Gentili M, Juhel A, and Bonnet F (1996) Peripheral analgesic effect of intra-articular clonidine. *Pain* **64:**593–596.

Genzen JR, Can Cleve W, and McGehee DS (2001) Dorsal root ganglion neurons express multiple nicotinic acetylcholine receptor subtypes. *J Neurophysiol* **86:**1771–1782.

Giordano J, Daleo C, and Sacks SM (1998) Topical ondansetron attenuates nociceptive and inflammatory effects of intradermal capsaicin in humans. *Eur J Pharmacol* **354:**R13–R14.

Giordano J and Roberts LV (1989) Peripherally administered serotonin 5-HT$_3$ receptor antagonists reduce inflammatory pain in rats. *Eur J Pharmacol* **170:**83–86.

Giordano J and Sacks SM (1997) Sub-anesthetic doses of bupivacaine or lidocaine increase peripheral ICS-205 930-induced analgesia against inflammatory pain in rats. *Eur J Pharmacol* **334:**39–41.

Gohil K, Bell JR, Ramachandran J, and Miljanich GP (1994) Neuroanatomical distribution of receptors for a novel voltage-sensitive calcium-channel antagonist, SNX-230 (omega-conopeptide MVIIC). *Brain Res* **653:**258–266.

Gottrup H, Bach FW, Arendt-Nielsen L, and Jensen TS (2000) Peripheral lidocaine but not ketamine inhibits capsaicin-induced hyperalgesia in humans. *Br J Anaesth* **85:**520–528.

Gould HJ III, Gould TN, England JD, Paul D, Liu ZP, and Levinson SR (2000) A possible role for nerve growth factor in the augmentation of sodium channels in models of chronic pain. *Brain Res* **854:**19–29.

Grando SA, Kist DA, Qi M, and Dahl MV (1993) Human keratinocytes synthesize, secrete and degrade acetylcholine. *J Investig Dermatol* **101:**32–36.

Hall JM (1992) Bradykinin receptors: pharmacological properties and biological roles. *Pharmacol Ther* **93:**131–190.

Hall KE, Liu J, Sima AAF, and Wiley JW (2001) Impaired inhibitory G-protein function contributes to increased calcium currents in rats with diabetic neuropathy. *J Neurophysiol* **86:**760–770.

Hamilton SG and McMahon SB (2000) ATP as a peripheral mediator of pain. *J Auton Nerv Syst* **81:**187–194.

Hamilton SG, Wade A, and McMahon SB (1999) The effects of inflammation and inflammatory mediators on nociceptive behaviour induced by ATP analogues in the rat. *Br J Pharmacol* **126:**326–332.

Hamilton SG, Warburton J, Bhattacharjee A, Ward J, and McMahon SB (2000) ATP in human skin elicits a dose-related pain response which is potentiated under conditions of hyperalgesia. *Brain* **123:**1238–1246.

Hassan AHS, Ableitner A, Stein C, and Herz A (1993) Inflammation of the rat paw enhances axonal transport of opioid receptors in the sciatic nerve and increases their density in the inflamed tissue. *Neuroscience* **55:**185–195.

Hautkappe M, Roisen MF, Toledano A, Roth S, Jeffries JA, and Ostermeier AM (1998) Review of the effectiveness of capsaicin for painful cutaneous disorders and neural dysfunction. *Clin J Pain* **14:**97–106.

Helyes Z, Németh J, Pintér E, and Szolcsányi J (1997) Inhibition by nociceptin of neurogenic inflammation and the release of SP and CGRP from sensory nerve terminals. *Br J Pharmacol* **121:**613–615.

Hersh EV, Pertes RA, and Ochs HA (1994) Topical capsaicin – pharmacology and potential role in the treatment of temperomandibular pain. *J Clin Dent* **5:**54–59.

Heyneman CA, Lawless-Liday C, and Wall GC (2000) Oral versus topical NSAIDs in rheumatic diseases. A comparison. *Drugs* **60:**555–574.

Hill R (2000) NK$_1$ (substance P) receptor antagonists – why they are not analgesic in humans? *Trends Pharmacol Sci* **21:**244–246.

Hirota K and Lambert DG (1996) Ketamine: its mechanism(s) of action and unusual clinical uses. *Br J Anaesth* **77:**441–444.

Hohmann AG, Briley EM, and Herkenham M (1999) Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. *Brain Res* **822:**17–25.

Hohmann AG and Herkenham M (1999a) Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. *Neuroscience* **90:**923–931.

Hohmann AG and Herkenham M (1999b) Cannabinoid receptors undergo axonal flow in sensory nerves. *Neuroscience* **92:**1171–1175.

Holzer P (1988) Local effector functions of capsaicin-sensitive sensory nerve endings: involvement of tachykinins, calcitonin gene-related peptide and other neuropeptides. *Neuroscience* **24:**739–768.

Holzer P (1991) Capsaicin: cellular targets, mechanisms of action and selectivity for thin sensory neurons. *Pharmacol Rev* **43:**143–201.

Hong JL, Ho CY, Kwong K, and Lee LY (1998) Activation of pulmonary C fibres by adenosine in anaesthetized rats: role of adenosine A$_1$ receptors. *J Physiol* **508:**109–118.

Hong Y and Abbott FV (1994) Behavioural effects of intraplantar injection of inflammatory mediators in the rat. *Neuroscience* **63:**827–836.

Hunter JC (1999) Voltage-gated ion channel modulators, in *Novel Aspects of Pain Management*: *Opioids and Beyond* (Sawynok J and Cowan A eds) pp 321–344, Wiley-Liss, New York.

Hunter JC, Gogas KR, Hedley LR, Jacobson LO, Kassotakis L, Thompson J, and Fontana DJ (1997) The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain. *Eur J Pharmacol* **324:**153–160.

Inoue M, Kobayashi M, Kozaki S, Zimmer A, and Ueda H (1998) Nociceptin/orphanin FQ-induced nociceptive responses through substance P release from peripheral nerve endings in mice. *Proc Natl Acad Sci USA* **95:**10949–10953.

Jackson DL, Graff CB, Richardson JD, and Hargreaves KM (1995) Glutamate participates in the peripheral modulation of thermal hyperalgesia in rats. *Eur J Pharmacol* **284:**321–325.

Jänig W, Levine JD, and Michaelis M (1996) Interactions of sympathetic and primary afferent neurons following nerve injury and tissue trauma. *Prog Brain Res* **113:**161–184.

Janscó G, Kiraly E, and Janscó-Gábor A (1977) Pharmacologically induced selective degeneration of chemosensitive primary sensory neurones. *Nature (Lond)* **270:**741–743.

Jarvis MF and Kowaluk EA (2001) Pharmacological characterization of P2X$_3$ homomeric and heteromeric channels in nociceptive signaling and behavior. *Drug Dev Res* **52:**220–231.

Jinks SL and Carstens E (1999) Activation of spinal wide dynamic range neurons by intracutaneous microinjection of nicotine. *J Neurophysiol* **82:**3046–3055.

Jones MJ (2000) Chronic neuropathic pain: pharmacological interventions. The new millennium. A theory of efficacy. *Int J Pharmaceutical Compounding* **4:**6–15.

Joshi W, Reuben SS, Kilaru PR, Sklar J, and Maciolek H (2000) Postoperative analgesia for outpatient arthroscopic knee surgery with intraarticular clonidine and/or morphine. *Anesth Analg* **90:**1102–1106.

Kalso E, Smith L, McQuay HJ, and Moore RA (2002) No pain, no gain: clinical

excellence and scientific rigour – lessons learned from IA morphine. *Pain* **98:**269–275.

Karlsten R, Gordh T, and Post C (1992) Local antinociceptive and hyperalgesic effects in the formalin test after peripheral administration of adenosine analogues in mice. *Pharmacol Toxicol* **70:**434–438.

Kenins P (1982) Response of single nerve fibres to capsaicin applied to the skin. *Neurosci Lett* **29:**83–88.

Kessler W, Kirchhoff C, Reeh P, and Handwerker HO (1992) Excitation of cutaneous afferent nerve endings in vitro by a combination of inflammatory mediators and conditioning effect of substance P. *Exp Brain Res* **91:**467–476.

Khasar SG, Green PG, Chou B, and Levine JD (1995) Peripheral nociceptive effects of α$_2$-adrenergic receptor agonists in the rat. *Neuroscience* **66:**427–432.

Kim KJ, Yoon YW, and Chung JM (1997) Comparison of three rodent neuropathic pain models. *Exp Brain Res* **113:**200–206.

Kingery WS (1997) A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes. *Pain* **73:**123–139.

Kingery WS, Guo TZ, Davies MF, Limbird L, and Maze M (2000) The α$_{2A}$ adrenoceptor and the sympathetic postganglionic neuron contribute to the development of neuropathic heat hyperalgesia in mice. *Pain* **85:**345–358.

Kirkup AJ, Eastwood C, Grundy D, Chessell IP, and Humphrey PPA (1998) Characterization of adenosine receptors evoking excitation of mesenteric afferents in the rat. *Br J Pharmacol* **125:**1352–1360.

Kolesnikov Y and Pasternak GW (1999a) Topical opioids in mice: analgesia and reversal of tolerance by a topical N-methyl-D-aspartate antagonist. *J Pharmacol Exp Ther* **290:**247–252.

Kolesnikov Y and Pasternak GW (1999b) Peripheral blockade of topical morphine tolerance by ketamine. *Eur J Pharmacol* **374:**R1–R2.

Kowaluk EA and Jarvis MF (2000) Therapeutic potential of adenosine kinase inhibitors. *Expert Opin Investig Drugs* **9:**551–564.

Krajnik M, Zylicz Z, Finlay I, Luczak J, and van Sorge AA (1999) Potential uses of topical opioids in palliative care - report of 6 cases. *Pain* **80:**121–125.

Kress M and Reeh PW (1996) Chemical excitation and sensitization in nociceptors, in *Neurobiology of Nociceptors* (Cervero F and Belmonte C, eds) pp 258–297, Oxford University Press, Oxford, UK.

LaMotte RH, Shian CN, Simone DA, Tsai E, and Fun P (1991) Neurogenic hyperalgesia: psychophysical studies of underlying mechanisms. *J Neurophysiol* **66:**190–211.

Laudron PM (1984) Axonal transport of opiate receptors in capsaicin-sensitive neurons. *Brain Res* **294:**157–160.

Lawland NB, McNearney T, and Westlund KN (2000) Amino acid release into the knee joint: key role in nociception and inflammation. *Pain* **86:**69–74.

Lawland NB, Willis WD, and Westlund KN (1997) Excitatory amino acid receptor involvement in peripheral nociceptive transmission in rats. *Eur J Pharmacol* **324:**169–177.

Lawson SN (1996) Peptides and cutaneous polymodal nociceptor neurons. *Prog Brain Res* **113:**369–385.

Lee DH, Liu Y, Kim HT, Chung K, and Chung JM (1999) Receptor subtype mediating the adrenergic sensitivity of pain behavior and ectopic discharges in neuropathic Lewis rats. *J Neurophysiol* **81:**2226–2233.

Lee HL, Yoon YW, Chung K, and Chung JM (1998) Comparison of sympathetic sprouting in sensory ganglia in three animal models of neuropathic pain. *Exp Brain Res* **120:**432–438.

Lener EV, Bucalo BD, Kist DA, and Moy RL (1997) Topical anesthetic agents in dermatologic surgery. *Dermatol Surg* **23:**673–683.

Leonard BE (1996) New approaches to the treatment of depression. *J Clin Psychiatry* **57 (Suppl 4):**26–33.

Leslie TA, Emson PC, Dowd PM, and Woolf CJ (1995) Nerve-growth factor contributes to the upregulation of GAP-43 and preprotachykinin A mRNA in primary sensory neurons following peripheral inflammation. *Neuroscience* **67:**753–761.

Levine JD, Clark R, Devor M, Helms C, Moskowitz MA, and Basbaum AI (1984) Intraneuronal substance P contributes to the severity of experimental arthritis. *Science (Wash DC)* **226:**547–549.

Levine JD, Fields HL, and Basbaum AI (1993) Peptides and the primary afferent nociceptor. *J Neurosci* **13:**2273–2286.

Levine JD, Moskowitz MA, and Basbaum AI (1985) The contribution of neurogenic inflammation in experimental arthritis. *J Immunol* **135 (Suppl 2):**843s–847s.

Levine JD and Reichling DB (1999) Peripheral mechanisms of inflammatory pain, in *Textbook of Pain* (Wall PD, Melzack R eds) 4th ed, pp 59–84, Churchill-Livingstone, Edinburgh.

Levine JD, Taiwo YO, Collins SD, and Tam JK (1986) Noradrenaline hyperalgesia is mediated through interaction with sympathetic post-ganglionic neurone terminals rather than activation of primary afferent nociceptors. *Nature (Lond)* **323:**158–160.

Lewin GR (1995) Neurotropic factors and pain. *Sem Neurosci* **7:**227–232.

Lewin GR, Rueff A, and Mendell LM (1994) Peripheral and central mechanisms of NGF-induced hyperalgesia. *Eur J Neurosci* **6:**1903–1912.

Lewis C, Neldhart S, Holy C, North RA, Buell G, and Suprenant A (1995) Coexpression of P2X$_2$ and P2X$_3$ receptor subunits can account for ATP-gated currents in sensory neurons. *Nature (Lond)* **377:**432–435.

Likar R, Koppert W, Blatnig H, Chiari F, Stein C, and Schäfer M (2001) Efficacy of peripheral morphine analgesia in inflamed, non-inflamed and perineural tissue of dental surgery patients. *J Pain Symptom Manage* **21:**330–337.

Likar R, Schäfer M, Paulak F, Sittl R, Pipman W, Schalk H, Geissler D, and Bernatzky G (1997) Intraarticular morphine analgesia in chronic pain patients with osteoarthritis. *Anesth Analg* **84:**1313–1317.

Likar R, Sittl R, Gragger K, Pipam W, Blatnig H, Breschan C, Schalk HV, Stein C, and Schäfer M (1998) Peripheral morphine analgesia in dental surgery. *Pain* **76:**145–150.

Liu XJ and Sawynok J (2000) Peripheral antihyperalgesic effects by adenosine A$_1$ receptor agonists and inhibitors of adenosine metabolism in a rat neuropathic pain model. *Analgesia* **5:**19–29.

Liu XJ, White TD, and Sawynok J (2000a) Potentiation of formalin-evoked adenosine release by an adenosine kinase and an adenosine deaminase inhibitor in the rat hindpaw: a microdialysis study. *Eur J Pharmacol* **408:**143–152.

Liu XJ, White TD, and Sawynok J (2000b) Amitriptyline increases local adenosine levels in the rat formalin model and a neuropathic pain model. *FASEB J* **14:**A1318.

Long TD, Cathers TA, Twillman R, O'Donnell T, Garrigues N, and Jones T (2001) Morphine-infused silver sulfadiazine (MIS) cream for burn analgesia: a pilot study. *J Burn Care Rehabil* **22:**118–123.

Low PA, Opfer-Gehrking TL, Dyck PJ, Litchy WJ, and O'Brien PC (1995) Double-blind, placebo-controlled study of the application of capsaicin cream in chronic distal painful polyneuropathy. *Pain* **62:**163–168.

Lynn B, Ye W, and Costell B (1992) The actions of capsaicin applied topically to the skin of the rat on C-fibre afferents, antidromic vasodilation and substance P levels. *Br J Pharmacol* **107:**400–406.

MacFarlane BV, Wright A, O'Callachan J, and Benson HAE (1997) Chronic neuropathic pain and its control by drugs. *Pharmacol Ther* **75:**1–19.

Machelska H, Binder W, and Stein C (1999) Opioid receptors in the periphery. *Prog Pain Res Manag* **14:**45–58.

MacPherson RD (2000) The pharmacological basis of contemporary pain management. *Pharmacol Ther* **88:**163–185.

Maekawa K, Minami M, Yabuchi K, Toya T, Katao Y, Hosoi Y, Onogi T, and Satoh M (1994) In situ hybridization study of μ- and κ-opioid receptor mRNAs in the rat spinal cord and dorsal root ganglia. *Neurosci Lett* **168:**97–100.

Malan TP, Ibrahim MM, Deng H, Liu Q, Mata HP, Vanderah T, Porreca F, and Makriyannis A (2001) CB$_2$ cannabinoid receptor-mediated peripheral antinociception. *Pain* **93:**239–245.

Malmberg AB and Yaksh TL (1994) Voltage-sensitive calcium channels in spinal nociceptive processing: blockade of N- and P-type channels inhibits formalin-induced nociception. *J Neurosci* **14:**4882–4890.

Malmberg AB and Yaksh TL (1995) Effect of continuous intrathecal infusion of omega-conopeptides, N-type calcium-channel blockers, on behavior and antinociception in the formalin and hot-plate tests in rats. *Pain* **60:**377–382.

Maneuf YP, Hughes J, and McKnight AT (2001) Gabapentin inhibits the substance P-facilitated K$^+$-evoked release of [^{3}H]-glutamate from rat caudal trigeminal nucleus slices. *Pain* **93:**191–196.

Mao J (1999) NMDA and opioid receptors: their interactions in antinociception, tolerance and neuroplasticity. *Brain Res Rev* **30:**289–304.

Mao J and Chen LL (2000) Gabapentin in pain management. *Anesth Analg* **91:**680–687.

Marchettini P, Lacerenza M, Marangoni C, Pellagata G, Sotjiu ML, and Smirne S (1992) Lidocaine test in neuralgia. *Pain* **48:**377–382.

Marks DR, Rapoport A, Padla D, Weeks R, Rosum R, Sheftell F, and Arrowsmith F (1993) A double blind placebo-controlled trial of intranasal capsaicin for cluster headache. *Cephalgia* **13:**114–116.

Martinez JH, Mondragon CE, and Céspedes A (1996) An evaluation of the antiinflammatory effects of intraarticular synthetic β-endorphin in the canine model. *Anesth Analg* **82:**177–181.

McArthur JC, Yiannoutsos C, Simpson DM, Adornato BT, Singer EJ, Hollander H, Marra C, Rubin M, Cohen BA, Tucker T, et al. (2000) A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. *Neurology* **54:**1080–1088.

McCarthy GM and McCarthy DJ (1992) Effect of topical capsaicin in the therapy of painful osteoarthritis of the hands. *J Rheumatol* **19:**604–607.

McCleane G (2000a) Topical doxepin hydrochloride reduces neuropathic pain: a randomized, double-blind, placebo-controlled study. *The Pain Clinic* **12:**47–50.

McCleane G (2000b) Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: a randomized, double-blind, placebo-controlled study. *Br J Clin Pharmacol* **49:**574–579.

McClesky EW and Gold MS (1999) Ion channels of nociception. *Annu Rev Physiol* **61:**835–856.

McCormack K, Kidd BL, and Morris V (2000) Assay of topically administered ibuprofen using a model of post-injury hypersensitivity. *Eur J Clin Pharmacol* **56:**459–462.

McGarraughty S, Chu KL, Wismer CT, Mikusa J, Zhu CZ, Cowart M, Kowaluk EA and Jarvis MF (2001) Effects of A-13497, a novel adenosine kinase inhibitor, on carrageenan-induced inflammatory hyperalgesia and locomotor activity in rats: evaluation of the sites of action. *J Pharmacol Exp Ther* **296:**501–509.

McMahon SB and Bennett DLH (1999) Trophic factors and pain, in *Textbook of Pain* (Wall PD and Melzack R eds) 4th ed, pp 105–128, Churchill-Livingstone, Edinburgh.

McMahon SB and Koltzenburg M (1992) Itching for an explanation. *Trends Neurosci* **15:**497–501.

McMahon SB, Lewin G, and Bloom SR (1991) The consequences of long-term topical capsaicin application in the rat. *Pain* **44:**301–310.

McMahon SB and Priestley JV (1995) Peripheral neuropathies and neurotrophic factors: animal models and clinical perspectives. *Curr Opin Neurobiol* **5:**616–624.

McNearney T, Speegle D, Lawand N, Lisse J, and Westlund KN (2000) Excitatory amino acid profiles of synovial fluid from patients with arthritis. *J Rheumatol* **27:**739–745.

Meller ST (1996) Ketamine: relief from chronic pain through actions at the NMDA receptor? *Pain* **68:**435–436.

Michael GJ, Averill S, Nitkunan A, Rattray M, Bennett DL, Yan Q, and Priestley JV (1997) Nerve growth factor treatment increases brain-derived neurotrophic factor selectively in TrkA-expressing dorsal root ganglion cells and in their central terminations within the spinal cord. *J Neurosci* **17:**8476–8490.

Michaelis M (2000) Coupling of sympathetic and somatosensory neurons following nerve injury: mechanisms and potential significance for the generation of pain, in *Proc 9th World Congress Pain. Progress in Pain Research and Management* (Devor M, Rowbotham MC and Wiesenfeld-Hallin Z, eds) vol 16, pp 645–656, IASP Press, Seattle, WA.

Millan MJ (1999) The induction of pain: an integrative review. *Prog Neurobiol* **57:**1–164.

Minami M, Kaekawa K, Yabuuchi K, and Satoh M (1995) Double in situ hybridization study on coexistence of μ-, δ- and κ-opioid receptor mRNAs with preprotachykinin A mRNA in the rat dorsal root ganglia. *Mol Brain Res* **30:**203–210.

Moon DE, Lee DH, Han HC, Xie J, Coggeshall RE, and Chung JM (1999) Adrenergic sensitivity of the sensory receptors modulating mechanical allodynia in a rat neuropathic pain model. *Pain* **80:**589–595.

Moore RA, Tramer MR, Carrol D, Wiffen PJ, and McQuay HJ (1998) Quantitative systematic review of topically applied non-steroidal anti-inflammatory drugs. *BMJ* **316:**333–338.

Morello CM, Leckband SG, Stoner CP, Moorhouse DF, and Sahagian GA (1999) Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. *Arch Intern Med* **159:**1931–1937.

Nakamura-Craig M and Gill BK (1991) Effect of neurokinin A, substance P and calcitonin gene related peptide in peripheral hyperalgesia in the rat paw. *Neurosci Lett* **124:**49–51.

Németh J, Helyes Z, Oroszi G, Thán M, Pintér E, and Szolcsányi J (1998) Inhibition of nociceptin on sensory neuropeptide release and mast cell-mediated plasma extravasation in rats. *Eur J Pharmacol* **347:**101–104.

Ninkovic M and Hunt S (1985) Opiate and histamine H1 receptors are present on some substance-P containing dorsal root ganglion cells. *Neurosci Lett* **53:**133–137.

Nolano M, Simone DA, Wendelschafer-Crabb G, Johnson T, Hazen E, and Kennedy WR (1999) Topical capsaicin in humans: parallel loss of epidermal nerve fibres and pain sensation. *Pain* **81:**135–145.

Novakovic SD, Kassotakis LC, Oglesby IB, Smith JAM, Eglen RM, Ford APDW, and Hunter JC (1999) Immunocytochemical localization of P2X$_3$ purinoceptors in sensory neurons in naive rats and following neuropathic injury. *Pain* **80:**273–282.

Nozaki-Taguchi N and Yaksh TL (1999) Characterization of the antihyperalgesic action of a novel peripheral mu-opioid receptor agonist - loperamide. *Anesthesiology* **90:**225–234.

Oida H, Namba T, Sugimoto Y, Ushikubi F, Oshishi H, Ichikawa A, and Narumiya S (1995) In situ hybridization studies of prostacyclin receptor mRNA expression in various mouse organs. *Br J Pharmacol* **116:**2828–2837.

Omote K, Kawamata T, Kawamata M, and Namiki A (1998) Formalin-induced release of excitatory amino acids in the skin of the rat hindpaw. *Brain Res* **787:**161–164.

Owolabi JB, Rizkalla G, Tehim A, Ross GM, Riopelle RJ, Kamboj R, Ossipov M, Bian D, Wegert S, Porreca F, et al. (1999) Characterization of antiallodynic actions of ALE-0540, a novel nerve growth factor receptor antagonist, in the rat. *J Pharmacol Exp Ther* **289:**1271–1276.

Padilla M, Clark GT, and Merrill RL (2000) Topical medication for orofacial neuropathic pain: a review. *J Am Dent Assoc* **131:**184–195.

Paice JA, Ferrans CE, Lashley FR, Shott S, Vizgirda V, and Pitrak D (2000) Topical capsaicin in the management of HIV-associated peripheral neuropathy. *J Pain Symptom Manage* **19:**45–52.

Pappagallo M, Gasparrone A, Tomai F, Iamele M, Crea F, and Gioffrè PA (1993) Analgesic effect of bamiphylline on pain induced by intradermal injection of adenosine. *Pain* **53:**199–204.

Parada CA, Tambeli CH, Cunha FQ, and Ferreira SH (2001) The major role of peripheral release of histamine and 5-hydroxytryptamine in formalin-induced nociception. *Neuroscience* **102:**937–944.

Park SK, Chung K, and Chung JM (2000) Effects of purinergic and adrenergic antagonists in a rat model of painful peripheral neuropathy. *Pain* **87:**171–179.

Pasternak GW (1998) The central questions in pain perception may be peripheral. *Proc Natl Acad Sci USA* **95:**10354–10355.

Pedersen JL, Galle TS, and Kehlet H (1998) Peripheral analgesic effects of ketamine in acute inflammatory pain. *Anesthesiology* **89:**58–66.

Perl E (1999) Causalgia, pathological pain and adrenergic receptors. *Proc Natl Acad Sci USA* **96:**7664–7667.

Pertovaara A and Wei H (2001) Peripheral effects of morphine in neuropathic rats: role of sympathetic postganglionic nerve fibers. *Eur J Pharmacol* **429:**139–145.

Price DD, Mao J, and Mayer DJ (1994) Central neural mechanisms of normal and abnormal pain states, in *Progress in Pain Research and Management* (Fields HL and Liebskind JC eds) vol 1, pp 61–84, IASP Press, Seattle.

Rains C and Bryson MH (1995) Topical capsaicin. A review of its pharmacological properties and therapeutic potential in post-herpetic neuralgia, diabetic neuropathy and osteoarthritis. *Drugs Aging* **7:**317–328.

Raja SN, Meyer RA, Ringkamp M, and Campbell JN (1999) Peripheral neural mechanisms of nociception, in *Textbook of Pain* (Wall PD and Melzack R eds) 4th ed, pp 11–57, Chruchill-Livingstone, Edinburgh.

Ramer MS and Bisby MA (1999) Adrenergic innervation of rat sensory ganglia following proximal or distal painful sciatic neuropathy: distinct mechanisms revealed by anti-NGF treatment. *Eur J Neurosci* **11:**837–846.

Ramer MS, Thompson SWN, and McMahon SB (1999) Causes and consequences of sympathetic basket formation in dorsal root ganglion. *Pain* **(Suppl 6):**S111–S120.

Rang HP, Bevan SJ, and Perkins MN (2000) Peripherally acting analgesic agents, in *Novel Aspects of Pain Management: Opioids and Beyond* (Sawynok J and Cowan A eds) pp 95–115, Wiley-Liss, New York.

Ren K, Thomas DA, and Dubner R (1995) Nerve growth factor alleviates a painful peripheral neuropathy in rats. *Brain Res* **699:**286–292.

Reuben SS and Connelly NR (1999) Postoperative analgesia for outpatient arthroscopic knee surgery with intraarticular clonidine. *Anesth Analg* **88:**729–733.

Rice ASC (2000) Cannabinoids and pain. *Curr Opin Investig Drugs* **2:**399–414.

Rice ASC, Farquhar-Smith WP, and Nagy I (2002) Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. *Prostaglandins Leukotrienes Essent Fatty Acids* **66:**243–256.

Richardson BP, Engel G, Donatsch P, and Stadler PA (1985) Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. *Nature (Lond)* **316:**126–131.

Richardson JD (2000) Cannabinoids modulate pain by multiple mechanisms of action. *J Pain* **1**:2–14.

Richardson JD, Kilo S, and Hargreaves KM (1998) Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. *Pain* **75**:111–119.

Ro LS, Chen ST, Tang LM, and Jacobs JM (1999) Effect of NGF and anti-NGF on neuropathic pain in rats following chronic constriction of the sciatic nerve. *Pain* **79**:265–274.

Robbins WR, Staats PS, Levine J, Fields HL, Allen RW, Campbell JN, and Pappagallo M (1998) Treatment of intractable pain with topical large-dose capsaicin: preliminary report. *Anesth Analg* **86**:579–583.

Roberts RGD, Stenensor JE, Westerman RA, and Pennefather J (1995) Nicotinic acetylcholine receptors on capsaicin-sensitive nerves. *Neuroreport* **6**:1578–1582.

Rowbotham MC, Davies PS, and Fields HL (1995) Topical lidocaine gel relieves postherpetic neuralgia. *Ann Neurol* **37**:246–253.

Rowbotham MC, Davies PS, Verkempinck C, and Galer BS (1996) Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. *Pain* **65**:39–44.

Rowbotham MC, Reisner-Keller LA, and Fields HL (1991) Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. *Neurology* **41**:1024–1028.

Rupniak NMJ and Hill RG (1999) Neurokinin antagonists, in *Novel Aspects of Pain Management: Opioids and Beyond* (Sawynok J and Cowan A, eds) pp 135–155, Wiley-Liss, New York.

Saria A, Martling CR, Elvar ZV, Theodorsson-Norheim E, Gamse R, and Lundberg JM (1988) Release of multiple tachykinins from capsaicin-sensitive sensory nerves in the lung by bradykinin, histamine, dimethylphenyl piperazinium and vagal nerve stimulation. *Am Rev Resp Dis* **137**:1330–1335.

Sato J and Perl ER (1991) Adrenergic excitation of cutaneous pain receptors induced by peripheral nerve injury. *Science (Wash DC)* **251**:1608–1610.

Sawynok J (1998) Adenosine receptor activation and nociception. *Eur J Pharmacol* **347**:1–11.

Sawynok J, Esser MJ, and Reid AR (1999a) Peripheral antinociceptive actions of desipramine and fluoxetine in an inflammatory and a neuropathic pain test in the rat. *Pain* **82**:149–158.

Sawynok J, Esser MJ, and Reid AR (2000a) Antidepressants as analgesics. An overview of central and peripheral mechanisms of action. *J Psychiatry Neurosci* **26**:21–28.

Sawynok J and Reid A (1997) Peripheral adenosine 5′-triphosphate enhances nociception in the formalin test via activation of a purinergic P2X receptor. *Eur J Pharmacol* **330**:115–121.

Sawynok J and Reid AR (2002) Modulation of formalin-induced behaviors and edema by local and systemic administration of dextromethorphan, memantine and ketamine. *Eur J Pharmacol* **450**:153–162.

Sawynok J, Reid AR, and Esser MJ (1999b) Peripheral antinociceptive action of amitriptyline in the rat formalin test: involvement of adenosine. *Pain* **80**:45–55.

Sawynok J, Reid AR, and Liu XJ (2000b) Involvement of mast cells, sensory afferents and sympathetic mechanisms in paw oedema induced by adenosine A_1 and $A_{2B/3}$ receptor agonists. *Eur J Pharmacol* **395**:47–50.

Sawynok J, Reid AR, and Poon J (1998) Peripheral antinociceptive effect of an adenosine kinase inhibitor, with augmentation by an adenosine deaminase inhibitor, in the rat formalin test. *Pain* **74**:75–81.

Sawynok J, Zarrindast MR, Reid AR, and Doak GJ (1997) Adenosine A_3 receptor activation produces nociceptive behaviour and edema by release of histamine and 5-hydroxytryptamine. *Eur J Pharmacol* **333**:1–7.

Schäfer M, Imai Y, Uhl GR, and Stein C (1995) Inflammation enhances peripheral μ-opioid receptor-mediated analgesia, but not μ-opioid receptor transcription in dorsal root ganglia. *Eur J Pharmacol* **279**:165–169.

Schmelz M and Kress M (1996) Topical acetylsalicylate attenuates capsaicin induced pain, flare and allodynia but not thermal hyperalgesia. *Neurosci Lett* **214**:72–74.

Segerdahl M and Sollevi A (1998) Adenosine and pain relief: a clinical overview. *Drug Dev Res* **25**:151–158.

Selley DE, Breivogel CS, and Childers SR (1993) Modification of G protein-coupled functions by low-pH pretreatment of membranes from NG108–15 cells: increase in opioid efficacy by decreased inactivation of G proteins. *Mol Pharmacol* **44**:731–741.

Shi TJS, Winzer-Serhan U, Leslie F, and Hökfelt T (2000) Distribution and regulation of α_2-adrenoceptors in rat dorsal root ganglia. *Pain* **84**:319–330.

Shimoyama N, Shimoyama M, Davis A, Inturrisi CE, and Elliott KJ (1997) Spinal gabapentin is antinociceptive in the rat formalin test. *Neurosci Lett* **222**:65–67.

Simone DA, Baumann TK, and LaMotte RH (1989) Dose-dependent pain and mechanical hyperalgesia in humans after intradermal injection of capsaicin. *Pain* **38**:99–107.

Simone DA, Ngeow JYF, Whitehouse J, Becerra-Cabal L, Putterman GJ, and LaMotte RH (1987) The magnitude and duration of itch produced by intracutaneous injections of histamine. *Somatosens Res* **5**:81–92.

Simone DA, Nolano M, Johnson T, Wendelschafer-Crabb G, and Kennedy WR (1998) Intradermal injection of capsaicin in humans produces degeneration and subsequent reinnervation of epidermal nerve fibres: correlation with sensory function. *J Neurosci* **18**:8947–8959.

Sindrup SH (1997) Antidepressants as analgesics, in *Anesthesia: Biologic Foundations* (Yaksh TL, Maze M, Lynch C, Bieguyck JF, Zampol WM and Saidman LJ eds) pp 987–997, Lippincott-Raven, Philadelphia.

Sindrup SH and Jensen TS (1999) Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. *Pain* **83**:389–400.

Skolnick P (1999) Antidepressants for the new millennium. *Eur J Pharmacol* **375**:31–40.

Smith PF and Corelli RL (1997) Doxepin in the management of pruritis associated with allergic cutaneous reactions. *Ann Pharmacother* **31**:633–635.

Snider WD and McMahon SB (1998) Tackling pain at the source: new ideas about nociceptors. *Neuron* **20**:629–632.

Stanton-Hicks M, Janig W, Hassenbusch S, Haddox JD, Boas R, and Wilson P (1995) Reflex sympathetic dystrophy: changing concepts and taxonomy. *Pain* **63**:127–133.

Steen KH and Reeh PW (1993) Actions of cholinergic agonists and antagonists on sensory nerve endings in rat skin in vitro. *J Neurophysiol* **70**:397–405.

Steen KH, Reeh PW, and Kreysel HW (1995) Topical acetylsalicylic, salicylic acid and indomethacin suppresses pain from experimental tissue acidosis in human skin. *Pain* **62**:339–347.

Steen KH, Reeh PW, and Kreysel HW (1996) Dose-dependent competitive block by topical acetylsalicylic and salicylic acid of low pH-induced cutaneous pain. *Pain* **64**:71–82.

Steen KH, Wegner H, and Meller ST (2001) Analgesic profile of peroral and topical ketoprofen upon low pH-induced muscle pain. *Pain* **93**:23–33.

Stein C (1993) Peripheral mechanisms of opioid analgesia. *Anesth Analg* **76**:182–191.

Stein C (1995) The control of pain in peripheral tissue by opioids. *N Engl J Med* **332**:1685–1690.

Stein C, Hassan AHS, Przerlocki R, Gramsch C, Peter K, and Herz A (1990) Opioids from immunocytes interact with receptor on sensory nerves to inhibit nociception in inflammation. *Proc Natl Acad Sci USA* **87**:5935–5939.

Stein C and Schäfer M (1997) Peripheral opioid analgesia: basic and clinical aspects. *Semin Anesth* **16**:112–116.

Stein C, Schäfer M, Cabot PJ, Carter L, Zhang Q, Zhou L, and Gasior M (1997) Peripheral opioid analgesia. *Pain Rev* **4**:173–187.

Stein C, Yassouridis A, Szopoko C, Helmke K, and Stein C (1999) Intraarticular morphine versus dexamethasone in chronic arthritis. *Pain* **83**:525–532.

Stow PJ, Glynn CJ, and Minor B (1989) EMLA cream in the treatment of postherpetic neuralgia. Efficacy and pharmacokinetic profile. *Pain* **39**:301–305.

Su X and Gebhart GF (1998) Effects of tricyclic antidepressants on mechanosensitive pelvic nerve afferent fibres innervating the rat colon. *Pain* **76**:105–114.

Sugimoto Y, Shigemoto R, Namba T, Negishi M, Mizuno N, Narumiya S, and Ichikawa A (1994) Distribution of the messenger RNA for the prostaglandin E receptor subtype EP3 in the mouse nervous system. *Neuroscience* **62**:919–928.

Taiwo YO and Levine JD (1990) Direct cutaneous hyperalgesia induced by adenosine. *Neuroscience* **38**:757–762.

Taiwo YO and Levine JD (1992) Serotonin is a directly-acting-hyperalgesic agent in the rat. *Neuroscience* **48**:485–490.

Tata AM, Plateroti M, Cibati M, Biagioni S, and Augusti-Tocco G (1994) Cholinergic markers are expressed in developing and mature neurons of chick dorsal root ganglia. *J Neurosci Res* **37**:247–255.

Tata AM, Vilaro MT, and Mengod G (2000) Muscarinic receptor subtype expression in rat and chick dorsal root ganglia. *Brain Res Mol Brain Res* **82**:1–10.

Taylor CP, Gee NS, Su TZ, Kocsic JD, Welty DF, Brown JP, Dooley DJ, Boden P, and Singh L (1998) A summary of mechanistic hypotheses of gabapentin pharmacology. *Epilepsy Res* **29**:233–249.

Tominaga M, Caterina MJ, Malmberg AB, Rosen TA, Gilbert H, Skinner K, Raumann BE, Basbaum AI, and Julius D (1998) The cloned capsaicin receptor integrates multiple pain-producing stimuli. *Neuron* **21**:531–543.

Torebjörk E, Wahren L, Wallin G, Hallin R, and Koltzenburg M (1995) Noradrenaline-evoked pain in neuralgia. *Pain* **63**:11–20.

Tracey DJ, Cunningham JE, and Romm MA (1995a) Peripheral hyperalgesia in experimental neuropathy: mediation by α 2-adrenoreceptors on post-ganglionic sympathetic terminals. *Pain* **60**:317–327.

Tracey DJ, Romm MA, and Yao NNL (1995b) Peripheral hyperalgesia in experimental neuropathy: exacerbation by neuropeptide Y. *Brain Res* **699**:245–254.

Treede RD, Meyer RA, Raja SN, and Campbell JN (1992) Peripheral and central mechanisms of cutaneous hyperalgesia. *Prog Neurobiol* **38**:397–421.

Tsuda M, Koizumi S, Kita A, Shigemoto Y, Ueno S, and Inoue K (2000) Mechanical allodynia caused by intraplantar injection of P2X receptor agonist in rats: involvement of heteromeric $P2X_{2/3}$ receptor signaling in capsaicin-insensitive primary afferent neurons. *J Neurosci* **20**:RC90.

Tsuzuki K, Kondo E, Fukuda T, Yi D, Tsujino H, Sakagami M, and Noguchi K (2001) Differential regulation of $P2X_3$ mRNA expression by peripheral nerve injury in intact and injured neurons in the rat sensory ganglia. *Pain* **91**:351–360.

Tverskoy M, Oren M, Vaskovich M, Dashovsky I, and Kissin I (1996) Ketamine enhances local anesthetic and analgesic effects of bupivacaine by a peripheral mechanism: a study in postoperative patients. *Neurosci Lett* **215**:5–8.

Twillman RK, Long TD, Cathers TA, and Mueller DW (1999) Treatment of painful skin ulcers with topical opioids. *J Pain Symptom Manage* **17**:288–292.

Vaile JH and Davis P (1998) Topcial NSAIDs for musculoskeletal conditons. A review of the literature. *Drugs* **56**:783–799.

Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. *Nature New Biol* **231**:232–235.

Vane JR, Bakhle YS, and Botting RM (1998) Cyclooxygenases 1 and 2. *Annu Rev Pharmacol Toxicol* **38**:97–120.

Vane JR and Botting J (1998) Selective COX-2 inhibitors. Pharmacology, clinical effects and therapeutic potential. Kluwer Academic Publishers, Dordrecht.

Walker K, Reeve A, Bowes M, Winter J, Wotherspoon G, Davis A, Schmid P, Gasparini F, Kuhn R, and Urban L (2001) mGlu5 receptors and nociceptive function II. mGlu5 receptors functionally expressed on peripheral sensory neurones mediate inflammatory hyperalgesia. *Neuropharmacology* **40**:10–19.

Warncke T, Jørum E, and Stubhaug A (1997) Local treatment with the N-methyl-D-aspartate receptor antagonist ketamine, inhibits development of secondary hyperalgesia in man by a peripheral action. *Neurosci Lett* **227**:1–4.

Warner TD and Mitchell JA (2002) Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum? *Proc Natl Acad Sci USA* **99**:13371–13373.

Watson CPN (1994) Topical capsaicin as an adjuvant analgesic. *J Pain Symptom Manage* **9**:425–433.

Watson CPN and Evans RJ (1992) The postmastectomy pain syndrome and topical capsaicin: a randomized trial. *Pain* **51**:375–379.

Watson CPN, Tyler KL, Rickers DR, Millikan LE, Smith S, and Coleman E (1993) A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia. *Clin Ther* **15**:510–526.

Watson CPN and Watt-Watson JH (1999) Treatment of neuropathic pain: focus on antidepressants, opioids and gabapentin. *Pain Res Management* **4:**168–178.

Waxman SG, Dib-Hajj S, Cummins TR, and Black JA (1999) Sodium channels and pain. *Proc Natl Acad Sci USA* **96:**7635–7639.

White DM and Cousins MJ (1998) Effect of subcutaneous administration of calcium channel blockers on nerve injury-induced hyperalgesia. *Brain Res* **801:**50–58.

Wilson JL, Nayanar V, and Walker JS (1996) The site of anti-arthritic action of the K-opioid U-50–488H, in adjuvant arthritis: importance of local administration. *Br J Pharmacol* **118:**1754–1760.

Wilson JL, Walker JS, Antoon JS, and Perry MA (1998) Intracellular adhesion molecule-1 expression in adjuvant arthritis in rats: inhibition by kappa-opioid agonist but not by NSAID. *J Rheumatol* **25:**499–505.

Winter J, Bevan S, and Campbell EA (1995) Capsaicin and pain mechanisms. *Br J Anaesth* **75:**157–168.

Wood JN, Coote PR, Minhas A, Mullaney I, McNeil M, and Burgess GM (1989) Capsaicin-induced ion fluxes increase cyclic GMP but not cyclic AMP levels in rat sensory neurones in culture. *J Neurochem* **53:**1203–1211.

Wood JN and Docherty R (1997) Chemical activators of sensory neurons. *Annu Rev Physiol* **59:**457–482.

Wood RM (2000) Ketamine for pain in hospice patients. *Int J Pharmaceutical Compounding* **4:**253–254.

Woolf CJ, Bennett GJ, Docherty M, Dubner R, Kidd B, Koltenburg M, Lipton R, Loeser JD, Payne R, and Toregfork E (1998) Towards a mechanism-based classification of pain? *Pain* **77:**227–229.

Woolf CJ and Decosterd I (1999) Implications of recent advances in the understanding of pain pathophysiology for the assessment of pain in patients. *Pain* **(Suppl 6):**S141–S147.

Woolf CJ and Doubell TP (1994) The pathophysiology of chronic pain - increased sensitivity to low threshold Aβ -fibre inputs. *Curr Opin Neurobiol* **4:**525–534.

Woolf CJ, Ma QP, Allchorne A, and Poole S (1996) Peripheral cell types contributing to the hyperalgesic action of nerve growth factor in inflammation. *J Neurosci* **16:**2716–2723.

Woolf CJ and Mannion RJ (1999) Neuropathic pain: aetiology, symptoms, mechanisms and management. *Lancet* **353:**1959–1964.

Woolf CJ, Safieh-Garabedian B, Ma QP, Crilly P, and Winter P (1994) Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity. *Neuroscience* **62:**327–331.

Woolf CJ and Salter SM (2000) Neuronal plasticity: increasing the gain in pain. *Science (Wash DC)* **288:**1765–1768.

Xiao W-H and Bennett GJ (1995) Synthetic ω -conopeptides applied to the site of nerve injury suppress neuropathic pains in rats. *J Pharmacol Exp Ther* **274:**666–672.

Yaksh TL (1999) Central pharmacology of nociceptive transmission, in *Textbook of Pain* (Wall PD and Melzack R eds) 4th ed, pp 253–308, Churchill-Livingstone, Edinburgh.

Yaksh TL, Dirig DM, and Malmberg AB (1998) Mechanism of action of nonsteroidal anti-inflammatory drugs. *Cancer Investig* **16:**509–527.

Yang LC, Chen LM, Wang CJ, and Buerkle H (1998) Postoperative analgesia by intra-articular neostigmine in patients undergoing knee arthroscopy. *Anesthesiology* **88:**334–339.

Young WS, Wamsley JK, Zarbin MA, and Kuhar MJ (1980) Opioid receptors undergo axonal flow. *Science (Wash DC)* **210:**76–78.

Zhou J, Chung K, and Chung JM (2001a) Development of purinergic sensitivity in sensory neurons after peripheral nerve injury in the rat. *Brain Res* **915:**161–169.

Zhou L, Zhang Q, Stein C, and Schäfer M (1998) Contribution of opioid receptors on primary afferent versus sympathetic neurons to peripheral opioid analgesia. *J Pharmacol Exp Ther* **286:**1000–1006.

Zhou S, Bonasera L, and Carlton SM (1996) Peripheral administration of NMDA, AMPA or KA results in pain behaviors in rats. *Neuroreport* **7:**895–900.

Zhou S, Komak S, Du J, and Carlton SM (2001b) Metabotropic glutamate 1α receptors on peripheral primary afferent fibers: their role in nociception. *Brain Res* **913:**18–26.

Zhou XF, Deng YS, Xian CJ, and Zhong JH (2000b) Neurotrophins from dorsal root ganglia trigger allodynia after spinal nerve injury in rats. *Eur J Neurosci* **12:**100–105.